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11. INTRODUCTION
Xanthine derivates belong to alkaloids which are described as natural bases having nitrogen 
atoms in molecular structure. Like other molecules of this major group xanthine derivates 
proper strong physiological effect on human and animal organism. The most famous sub-
stance of this group is caffeine - the tea and coffee culture has a several centuries long age. 
Firstly this substance was isolated and characterized in 1819 by German chemist Runge and 
since then it has been widely used in many areas including pharmacy. In pharmaceuticals 
caffeine is known to be applied as a medicine affecting nervous system. Two other derivat-
ives of xanthine – theophylline and theobromine have a long history of use in the treatment 
of  asthma.  Despite  of  losing competition  to  more  modern  pharmaceutically  active  sub-
stances (API) as corticosteroids and stimulators of β-adrenergic receptors, theophylline is 
still a commonly used medicine. Limited aqueous solubility and low physical stability are 
among factors, which hamper theophylline and theobromine use. However these problems 
can be solved and the general aim of this work was to find an appropriate approach. 
2. PROPERETIES OF XANTHINE DERIVATES
2.1. Structure and basic physicochemical properties
2.1.1. Molecular structure 
The parent molecule of this group is purine, which is known to be bi-cyclical hetero-cyclic 
ampholyte  - thus it has both acidic and alkaline activity (pKa-values 2.4 and 8.9) (Roth et 
al 1991). Purine is a well water-soluble substance and melts at 212 ºC. The molecular struc-
ture of this molecule is represented in the Figure 1.
2Figure 1. Molecular structure of purine (http://wikipedia.org).
A basic molecule of the group is a product of purine metabolism xanthine or 3,7-dihyro-
1H-purine-2,6-dione  (The  Merck  Index  2001).  Xanthine  is  known  to  exist  in  several 
tautomeric  forms,  the  most  stable  of  them is  9H (Roth  et  al  1991).  Other  natural  and 
synthetic  derivatives  of  this  group  like  caffeine  (1,3,7-trimethylxanthine),  theophylline 
(1,3-dimethylxanthine)  and  theobromine  (3,7-Dimethylxanthine)  are  called 
methylxanthines due to substituted methylene functional groups in either 1, 3 or 7-N-atom 
like it is represented in the Figure 2. Along with natural xanthines some synthetic products 
like  etofylline  and  enprofylline  are  also  used  in  pharmaceutical  practice.  Several 
pharmacokinetic parameters of these molecules can be improved by synthesis of molecular 
complexes  containing  xanthines  and  other  substances.  A  well  known  example  is  the 
theophylline-ephedrine complex. 
                      Caffeine                                           Theobromine                                         Theophylline
Figure 2. Structural formula of pharmaceutical xanthine derivates (http://wikipedia.org).
32.1.2. Basic physicochemical properties
As mentioned above, all xanthines belong to purine alkaloids and thus are naturally bases. 
Their  alkali  nature  is  quite  weak (Isaacson  1998)  and they  possess  relatively  low  pKa 
values, which are represented in Table 1 (Roth et al 1991). This phenomenon is explained 
by ability of nitrogen situated in position 9 to accept proton (Isaacson 1998). 
Table  1.  Physicochemical  propereties  of  natural  xanthine  derivates  (Pharmaceutical 
Chemistry, Volume 2: Drug Analysis 1991).
Substance Chemical
formula
Molecular
mass
pKa 
(basic)
pKa 
(acidic)
Melting 
point
(ºC)
Water 
solubility 
mg/ml 
(25 ºC)
Log P 
Caffeine C8H10N4O2 194.19 0.6  - 234-239 24.74 -0.07
Theophylline C7H8N4O2 180.16 0.3 8.6 270-274 8.33 -0.05
Theobromine C7H8N4O2 180.16 0.12 10.05 350 0.50 -0.67
As seen in table 1, theophylline and theobromine can act also as acids according to their 
ability to proton donation from position 7. Therefore they possess ampholytic nature like 
purine (Roth et al 1991). Acidic behavior of these molecules is also provided by keto-enole 
tautomeresation, which allows shift of hydrogen atom. Thus theophylline and theobromine 
are able to form salts both with acidic and basic substances (Ledwidge and Corrigan 1998). 
These molecules have stronger basic nature than acidic one  - salt formation with strong 
acid is shown to be more preferable. Unlike theobromine and theophylline caffeine has no 
this site in the structure and therefore tautomerisation becomes impossible. This explains a 
pure alkali nature of this substance.
All  derivatives  of  xanthine except  caffeine  are  known to have poor water  solubility  in 
contrast to their parent molecule purine. It is accounted for by such factors as strong inter-
base hydrogen bonds and base stacking (Bruns and Fergus 1989). The paradoxal effect of 
4enhanced solubility due to increasing of methylated groups number is explained by ability 
of  proton  elimination  and  following  hydrogen  bonding  site  formation.  Another  factor, 
which has noticeable effect on poor solubility nature of xanthine derivates is existence of 
relatively strong intramolecular bonds between N-H-groups (Roth et al 1991). The high 
values  of melting points  are based on the same phenomenon:  larger aggregates  require 
more energy and naturally more heat to change condition from solid to liquid. 
With respect to lipophility, xanthine derivates have different properties (Biagi et al 1990). 
As seen in the Table 1, all molecules belonging to this group have negative logP values and 
thus dissolve slightly in organic liquids like chloroform. Thus they’re hydrophilic and do 
not  penetrate  into organic  phase of binary solvent.  But  caffeine  and theophylline  show 
higher  lipophility  than  theobromine.  It  is  noteworthy  to  mention  a  weak  ability  of 
theobromine  to  stimulate  central  nervous  system  (CNS)  compared  to  other  relative 
substances.
2.2. Nature sources and way of synthesis
2.2.1 Occurrence and synthesis in nature
As mentioned above, all xanthines are products of purine metabolism. The final substance 
of this process is caffeine and it's formation goes throw several steps. The first of them is 
convertation of purine nucleotide to xanthonesine - the first  intermediate  (Ashihara and 
Croizer 2001). Next stage is a methylation with assistance of several methyltransferase-
enzymes as shown in Figure 3 (Ashiara et al 1997).
5Figure 3. The synthesis of caffeine (Ashiara et al 1997).
During  biosynthesis  of  caffeine  several  intermediates  appear  in  the  order:  7-
methylxanthinose,  7-methylxanthine,  3,7-methylxanthine  and theobromine.  This  process 
takes place in plants,  mostly in coffee and tea.  Presence of caffeine is  also detected in 
camilla-family,  cola,  herrania  and paulina  (Ashiara  and Croizer  2001).  Theobromine  is 
found in cocoa.  Besides production,  caffeine catabolism also takes place in plants.  The 
pathway of caffeine degradation is demethylation with demethylase-ferments. This chain 
terminates when the final product xanthine is decomposed through such intermediates as 
uric acid, allantonin and allantonic acid and dissosiates into carbone dioxide and ammonia. 
Theophylline is known to occur as a primary intermediate of caffeine catabolism in the 
plant. Xanthine synthesis also takes place in mammalians – such product as paraxanthine 
was found in their organisms.
2.2.2 Use of technologies in production and degradation of caffeine 
 
The most  common way of  caffeine  manufacturing  is  extraction  from tea  and coffee  in 
boiling  water.  It's  also  possible  to  make  caffeine  by  methylation  of  theophylline  or 
alternatively by synthesis  from urea.  On the other  hand, biotechnologies  are applied in 
degradation of caffeine and further production of other pharmaceutical xanthine derivates 
(Gokulakrishnan et al 2005). For example bacteria geners  Pseudomonas and  Serratia are 
6able  to  degenerate  caffeine  to  theobromine.  One  can  also  produce  theophylline  with 
assistance  of  Aspergillus,  Penicillinum and  Rhizopis  fungi.  The  first  two  species  have 
shown an ability to almost full-scale degradation. A separation of oxidase-enzymes or their 
biosynthesis is an alternative way of theophylline production.
2.3. Solid state properties
2.3.1. Polymorphism 
Polymorphism means  the  ability  of  same  chemical  substance  to  occur  in  two or  more 
crystalline  forms.  Like  many  pharmaceutical  ingredients,  xanthines  are  known to  have 
several  crystalline  structures.  Polymorphs  vary by such  physical  parameters  as  melting 
point, density, dissolution rate and hardness. Polymorphism is divided into two types - real 
and pseudo. There are two kinds of stable real polymorphs: enantiotropes and monotropes, 
which differ by the temperature ranges of stability. The former are able to transit reversibly 
below melting point, while the latter do not have this property. A metastable form, which 
can be also defined as a true polymorph, is characterized with physical stability of crystals 
under  certain  conditions  (Pirttimäki  et  al  1993).  Commonly metastable  form has  better 
physicochemical and biopharmaceutical properties than stable one, but also reverts easily 
with change of conditions. 
Pseudopolymorphism is the resultant of contact between solid form and liquids. Products of 
this  interaction  are  hydrates  (species  with  water  as  a  liquid  phase)  and  solvates  (other 
liquids). The mechanism is penetration of water molecules into the bulk solid structure and 
further  change  of  crystalline  structure  (Räsänen  et  al  2001).  The  role  of  this  sort  of 
polymorphism in pharmaceutical science is great because hydrates and solvates are known 
to have huge differences in pharmacokinetic profiles compared to non-hydrous crystals. 
Theophylline  has  great  hydration  ability  and  there  exist  two  forms:  monohydrate  and 
anhydrate.  A hydration  process commonly occurs in  humid conditions  where substance 
7takes easily contact with water. The relative air humidity (RH) is claimed high when a 
value is over 79% (Amado et al 2007). About one third of pharmaceutical compounds are 
able to form hydrates under such humid conditions. Theophylline absorbs actively water 
molecules during manufacturing process of pharmaceutical  dosage forms (Herman et  al 
1988). 
Hydration of theophylline includes absorption of water molecules into the surface of crystal 
followed  by  deep  diffusion  (Amado  et  al  2007).  Finally,  hydrogen  bonds  are  formed 
between water and the solid state. The next step is a formation of water tunnels, which 
assist penetration of greater aqua volumes. The strength of hydrate is dependent on their 
number  and also on the strength of hydrogen bonds (Airaksinen et  al  2004).  The final 
structure  is  known  to  have  two  water  molecules  with  hydrogen  bonded  into  two 
theophylline molecules (Suihko et al 1997).
As it  is  typical  for pseudopolymorphic  forms,  theophylline  anhydrate  and monohydrate 
have differences in physicochemical habits. For example, anhydrous theophylline melts at 
271 ºC and this process occurs in 3 steps (Phandis and Suryanaraynan 1997). When heat 
overtakes the value of 79 ºC dehydration takes place, in the next stage - 179 ºC, aqueous 
molecules  vaporize  and  finally  when  temperature  achieves  a  value  of  271  ºC  solid 
anhydrous transforms into a liquid condition. Also differences in the density are noticeable 
(Suihko et al 2001). The anhydrate is known to have density of 1.470 g/cm3 compared to 
value 1.478 g/cm3 in case of monohydrate. These two forms vary also in such parameter as 
water solubility: anhydrous theophylline dissolves better than the monohydrous form one 
(Shefeter and Higuchi 1963). 
Anhydrous theophylline appears as two stable crystalline lattices named as form I and II 
(Suzuki  et  al  1989).  These  crystalline  states  are  supposed  to  be  formed  during  heat 
transition  occurring  during  dehydration  of  monohydrous  form.  This  process  is  going 
through drying of solid theophylline monohydrate and also includes two stages: breaking of 
hydrogen bonds and further evaporation of the loosened water (Suihko 1997). Dehydration 
8is dependent on such factors as surface area and temperature – increase of temperature 
improves the result (Agbada and York 1994). Humidity is shown to be the third factor, 
which affects the rate and quality of drying – contrary to previous variables, decrease of it's 
value gives better result. Because the transition takes place under influence of temperature, 
both  polymorphic  forms  of  anhydrous  theophylline  differ  in  energetic  profiles,  melting 
points and densities (Suzuki et al 1989). The data are represented in Table 2.
Table 2. Physocochemical propereties of theophylline polymorphs (Suzuki et al 1989).
Polymorph Melting point (ºC) Density (g/cm3) Enthalpy change 
(kJ/mol)
Form I 273.4±1.0 1.489 26.4±0.3
Form II 269.1±0.4 1.502 28.2±1.1
As  explained  above,  the  crystal  lattice  of  anhydrous  theophylline  is  maintained  by 
hydrogen bonds between nitrogen and hydrogen atoms as it's shown in Figure 4 (Track et al 
2006).  Theophylline  is  also  shown  to  form crystals  in  one  dimension  if  energetically 
favorable angles are available (Carlucci and Gavezzotti 2005). The crystals of theophylline 
are shown to be quite strong.
Figure 4. Crystal form of anhydrous theophylline (Track et al 2006).
Form II of anhydrous theophylline was shown to have more advantageous  properties in 
terms of stability and solubility.  It dissolves better and does not revert to hydrate in room 
temperature. Due to this reason, it is the most commonly used form in formulations of solid 
dosage forms containing theophylline.
9Theophylline  is  known to occur  also as a  metastable  crystalline  structure (Phandis  and 
Suryanaraynan  1997).  This  form  is  noticed  during  drying  of  monohydrate  being  an 
intermediate of current process. The volume of metastable phase is shown to decrease with 
increasing of temperature and drying time (Airaksinen et al 2004). 
Caffeine appears also as anhydrate and hydrate (Edwards et al 1997). The site of hydrogen 
interaction in caffeine is nitrogen atom situated in 9-position. Being the only place for this 
type of bonding it can provide only a weak type of hydrate. This statement is based also on 
longer distances between current molecule and water (Carlucci and Gavezzotti 2005). It 
must be noticed that intramolecular distances in the caffeine lattice are respectively short. 
The predominant  sort of interaction is in this  case is electrostatic.  Having such type of 
interactions, aqueous molecules are able to move free and thus hydrous structure of caffeine 
is  unstable  compared  to  theophylline  monohydrate.  Enthalpy  value  of  31.2  kJ/mol-1 
(Edwards et al 1997) is markedly lower compared to that of theophylline (49.7 kJ/mol-1). 
Thus dehydration of caffeine requires less heat (Suzuki et al 1985). Another affecting factor 
is the surface area.
Caffeine anhydrate occurs also as two solid polymorphs - stable (β) and metastable  (α) 
(Edwards et al 1997). The first one showed to have better stability in high temperature. The 
β-phase  forms  as  a  final  product  of  dehydration  process  and  α-phase  appears  during 
heating. The metastable caffeine polymorph shows to have ability to revert back into the 
stable in room temperature. This transformation does not require energy and thus there has 
not  been  noticed  radical  change  in  the  structure  of  crystal  lattice.  An  absence  of  full 
regular-ordered crystal lattice can be claimed as a reason (Carlucci and Gavezzotti 2005). 
More stable parallel and less stable perpendicular rigid forms are known to exist. Phase 
transition  rate  in  solid  anhydrous  caffeine  is  dependent  on  heat  and  independent  on 
moisture  (Matsuo  and  Matsuoka  2007b).  A  form  conversion  also  takes  place  during 
grinding process and its rate is related to the grinding rate (Pirttimäki et al 1993). 
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With  respect  to  the  physicochemical  properties,  both  polymorphs  of  caffeine  vary  by 
density,  which is  equal to 1.5 g/cm3 in α-form and 1.446 g/cm3 in β-form (Cesaro and 
Srarec 1980). The heat of transition occurs at 141 ºC and enthalpy is 4.1 kJ/mol-1 (Bothe 
and Cammenga 1980). Hydration (Pirttimäki and Laine 1994) and solubility profiles are 
also different (Wyttehbach et al  2007). As expected,  metastable form of caffeine forms 
hydrate quickly and dissolves better.  
2.3.2 Salts
All xanthine derivates except caffeine are ampholytes and thus they are available for salt 
formation both with strong acids and bases. Construction of salts occurs on ionizing sites of 
xanthines.  This  process  is  usually  applied  for  improvement  of  solubility  and  further 
enhancement  of  bioavailability.  Enhancement  of  those  parameters  also  gives  large 
possibilities for new formulations.
Such  salts  of  theophylline  as  sodium acetate,  glycinate  (The  Mecrk  Index  2001),  and 
olamine  are  used  in  pharmaceutical  practice  (Sedam and  Osol  1965).  Theobromine  is 
known  to  exist  as  calcium  and  sodium  salicylates  (The  Merck  Index  2001),  caffeine 
according to own alkali nature forms salts only with anions and the only pharmaceutically 
available complex is hydrochloride dehydrate. 
2.4 Pharmacology of xanthines
2.4.1 Pharmacodynamics
Derivatives  of  xanthine  belong  to  the  pharmacological  group  of  adenosine  A-receptor 
antagonists  (Daly  2007).  Three  types  of  these  receptors  are  known  -  A1,  A2 and  A3. 
Pharmacological  action of these substances goes through inhibition  of cyclic  GMP and 
GABAA-receptors. Theophylline, theobromine and caffeine have anti-inflammatory effect 
and  thus  (mostly  theophylline)  are  used  in  the  treatment  of  asthma.  Other  important 
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therapeutic areas of xanthines are Alzheimer's disease and cancer and they are applied as 
heart and vascular agents due to diuretic effect. Having excellent CNS-penetration ability 
caffeine is also available as a stimulant and antidepressant.
2.4.2 Pharmacokinetics and formulations
Xanthines show good in vivo intake profiles and are well absorbed in GI-tract (Sedam and 
Osol  1965).  Peak  plasma  concentration  for  theophylline,  theobromine  and  caffeine  is 
achieved quickly.  Half-life  is  not long and thus they belong to short-acting substances. 
Xanthine derivates are delivered in per-oral forms as tablets, capsules and mixtures both for 
rapid release and for prolonged action.
3. BASIS OF SOLUBILITY
3.1. General statements
Solubility is a thermodynamic process taking place when a chemical substance existing in a 
solid state takes contact with a liquid solvent. As result, chemical bonds form whose type 
depends strongly both on the solvate and solvent properties. Solubility can be described 
with  weight,  molecular  and  energetic  profiles.  It  has  significance  in  a  pharmaceutical 
practice due to the fact  that  the pharmacokinetic  parameters  and natural  possibilities  of 
formulations depend greatly on it (Zhong and Hu 2003). 
Such factors as solid  state crystalline structure,  temperature,  pressure have an effect  on 
aqueous solubility (Shefeter and Higuchi 1963). There is a noticeable relation between the 
particle size and surface area of solid solute (Perrut et al 2005 I). Another important factor 
is the activity coefficient of both phases (Ruckenstein and Shulgin I 2003).  
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According to data presented in European Pharmacopoeia, substances are classified by their 
solubility profiles in the conditions of room temperature (15-25 ºC) as represented in Table 
3.
Table 3. Solubility classification (European Pharmacopoeia, supplement 5.7.).
Descriptive term Approximate volume of solvent in millilitres per gram of solute
Very soluble less than 1
Freely soluble form 1 To 10
Soluble from 10 To 30
Sparingly soluble from 30 To 100
Slightly  soluble from 100 To 1000
Very slightly soluble from 1000 To 10 000
Practically insoluble more than 10 000
3.2 Theoretical basis
3.2.1 Measurement of solubility 
The  solubility  is  a  dynamic  process,  which  occurs  as  a  dissociation  of  solid  chemical 
substance in liquid medium. It's described with Equation 1 (Shefeter and Higuchi 1963):
                   Ks
Asolid ↔ Aliquid                                                              (Equation 1) 
Where  factor  A  means  soluble  compound  and  Ks is  equilibrium  constant,  which  has 
different  values  in  various  temperature  and  pressure  ranges.  This  symbol  represents 
solubility coefficient and is counted in several way shown in Equation 2 (Sedam and Osol 
1965):
log (KS, T2 / KS, T1)  = ∆H (T2-T1) / 2.3 R T1T2                              (Equation 2)
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KS is saturation at temperature T1.  KS means solubility at temperature  T2.  ∆H  is equal to 
enthalpy value and  R is  a gas constant.  In case when compound exists  in one or more 
species (polymorphs, salts) the equilibrium  takes such form (Equation 3): 
                                                  Ksp
A:nBsolid ↔ Aliquid +Bliquid                                                        (Equation 3) 
Coefficient  Ksp is  equal  to  multiplied  concentrations  of  compounds  (CA and CB)  as  it's 
shown in Equation 4:
Ksp = [CA] [CB]n                                                                 (Equation 4)
Knowledge  of these  parameters  gives  opportunities  for  determination  of  total  drug 
solubility (Serajuddin 2007). Based on the fact that xanthines are alkali, this Equation can 
be presented as: 
St (B) = Ks (1 + Kb [OH-])                                                  (Equation 5)
Usually it is needed to measure a rate of dissolution (Shefeter and Higuchi 1963). In this 
case concentration of saturated solution (CS) is measured as solubility (euquation 6): 
    
                                  dC / dT = k (Cs - Ct)                                                             (Equation 6)
Ct is equal to amount dissolved in time  t and k is respectively coefficient dependent on 
temperature, pressure, particle shape, size and surface area. This system plays role in cases 
when the quota of solubility and concentration in time unit is much more less than 1. The 
importance of surface area and thus particle size and shape is described in the Fick's law 
which is represented as Equation 7 (Perrut and Leboeuf  I 2005):
       dm / dt = -h S (Cs - Cb)                    (Equation 7)
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Coefficient Cb means in this equation bulk concentration of solid, S area and thus h is mass 
transfer coefficient which is calculated as diffusion coefficient D divided into the thickness 
of  layer  e.  For  polymorphic  systems  the  correct  determination  way  is  represented  in 
Equation 8 (Shefeter and Higuchi 1963):
                 G = (K DA KSP – k DA C A) / CB        (Equation 8)
3.2.2 Estimation of solubility
Estimation  of  aqueous  solubility,  which  is  required  for  formulation  testing  can  be 
performed in different ways. They are divided in three main groups: structure-estimations, 
physicochemical  estimations  and  correlations  (Zhong  and  Hu  2003).  All  of  them  are 
calculated with utilization of data about compound molecular structure. A good example of 
the first type technique is connectivity index, which depends on the number of sites able to 
form hydrogen bonds and the presence of hydrophobic groups having significant effect on 
the solubility. Solubility prediction by exploitation of such physicochemical parameters as 
melting and boiling point, coefficient of distribution etc is done with assistance of Equation 
9 (Peterson and Yalkowsky 2001):
Log SW = 0.5 - 0.01 (MP - 25) – log KW        (Equation 9)
The third group of measurements includes determination of maximum ability of substance 
to be dissolved (Martin et al 1981). It's purpose is to compare ideal molar solubility against 
solubility given as practical results. It can be applied to both aqueous and binary systems.
3.2.3 Solubility measurement in pharmaceutical practice
According  to  official  requirement  it's  essential  to  measure  solubility  of  both  pure 
pharmaceutical ingredients and solid formulations. When it's necessary to determine this 
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parameter  for  pure  ingredient  a  test  compound  must  be  dissolved  in  a  special  vessel. 
Concentration  measurement  is  performed  in  the  next  step  with  application  of  different 
chromatography methods, for example HPLC. 
In case of solid per-oral formulations (tablets, capsules, granules) European Pharmacopoeia 
requires to test them with four different apparatus. The first one is basket, which consists of 
vessel, motor and driving shaft. The test is going through rotation. In the paddle apparatus 
compound is placed on the bottom and the propeller  moves water which temperature is 
maintained at the needed level, commonly 37 ºC. In the reciprocating cylinder dissolution 
is driven by movements of both cylinders. The forth is flow-through-cell which is designed 
to maintain the inner flow of medium.
4. COMMON TECHNIQUES OF SOLUBILITY IMPROVEMENT
4.1 Binary solvents
Binary  solvents  are  described  as  systems  consisting  of  water  and  organic  co-solvent. 
They’re  mostly  applied  when  a  pharmaceutically  active  ingredient  having  poor-water 
solubility profile needs to be formulated as an oral solution (Grünbauer et al 1986). For 
achieving enhancement of solubility, there must be added one or more non-toxic organic 
co-solvent, for example acetic acid or propylene glycol. This way is based on the ability of 
non-polar organic liquid to dissolve numerous drug molecules (Li and Yalkowsky 1994). 
The binary solvents include three phases: solid solvate and two liquids (Grünbauer et al 
1986).  In some cases a tertiary system occurs: water plus two organic phases. Adding of 
ethanol as a co-solvent is common due to its great solvent potential. The final composition 
of co-solvent system is dependent on such factors as mole fraction (x) and Raoult's activity 
coefficient (γ), in concordance with basic thermodynamics it's described as Equation 10:
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xi + γi = xi' + γi'                                                    (Equation 10)
The activity coefficient is shown to be a factor, which describes also volume of Van der 
Waals interaction (Williams and Amidon II 1984). There exist such variables as surface 
area  of  molecules  and  radius  between  them.  Other  affecting  factors  are  pressure  and 
temperature. This data are used for estimation of intermolecular interplay parameter (A), 
which varies for molecules existing in different phases. Knowing it one can determine the 
value of free energy W which depends on the difference between ideal and actual energy. 
Thus there're known noticeable variables of it in each system (Martin et al 1981). With 
knowledge of free energy, one is able to measure solubility parameter  δ which relates to 
molar fraction as it’s shown in Equation 11.
      ∆ = δ1 δ2 - W                                                               (Equation 11) 
               
According to this formula, both solid and liquid phase have own current parameter. Thus δ1  
describes  ability  of  non-polar  solvent  to  dissolve  solid  compound  and  δ2 refers  to 
hydrophobity  of  the  last  one.  Current  factor  has  strong  dependence  on  the  dielectric 
constant ε of molecular phase as it is represented in Equation 12: 
                          δ = 7.5 + 0.22ε                                                              (Equation 12) 
Knowing values of free energy and solubility, it is possible to estimate the mole fraction 
solubility (X) or maximum molar solubility of the drug. By this parameter is meant property 
to  maintain  constant  value  in  certain  volume,  temperature,  density,  molar  volume  and 
fraction. However the factor of free energy shows to be valid only for disperse systems 
(Williams and Amidon I 1984). Another noticeable weakness is requirement to have data 
about  numerous  factors.  The  easiest  alternative  way to  approach  solubility  profile  and 
maximum of it is the Hildebrand method (Escalera et al 1994). For solubility estimation it 
is  essential  to  be aware  about  volume fraction  of  solvent  (φ1),  molar  volume (V2)  and 
17
solubility for each phase parameters. Hildebrand's law formula is represented as Equation 
13:
            ∆H2 = V2 φ12(δ1- δ2)2                                                         (Equation 13)
This law is also valid for ampholytic substances like xanthine derivates and thus both acidic 
and  basic  components  have  own  solubility  Hildebrand's  parameters’  values  which  are 
represented as δa and δb. Thus the Equation 14 changes to Equation 14:
∆H2ab=V2 φ12 (δ1a - δ2a) (δb - δ2b)                                                    (Equation 14)
Unlike  previous  models,  Hildebrand's  equation  takes  into  account  also hydrogen  bonds 
which usually take place in binary solvent due to polar interaction. Thus the ideal solubility 
volume measurement is possible to perform as it’s represented in Equation 15:
ln X2 = A (δ1 - δ2)2 + B (δ1a - δ2a) (δ1b - δ2b)                                  (Equation  15) 
                                                                   
Also knowing of  lipophility  profile  can help  to  predict  solubility  of  solid  substance  in 
binary solvents (Williams and Amidon II 1984). There exists constant known as C2 which 
measures the interaction between solute and both solvents. Naturally it depends on value of 
logP. Another way to utilize hydrophobity of solid compound is estimation through log-
linear model, which uses such variables as solubility in water (Sw) and in co-solvent (Sc). 
Third important factor is the molar fraction of each solvent (f) (Li and Yalkowsky 1994). 
Thus solubility or Sm is calculated according to equation 16: 
Log Sm = f log Sc + (1-f) log Sw                                                   (Equation 16)
Solubility profile is represented in this case as a slope of current function and thus takes a 
form of Equation 17:
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σ = log (Sc / Sw)           (Equation 17) 
The slope and lipophility correlate  well  in case of binary solvent systems.  This sort  of 
mixture can be prepared in different proportions - ideal and non-ideal (Ruckenstein and 
Shulgin II 2003). An ideal mixture means a system where pairs of molecules have identical 
energy profiles  (Grünbauer  et  al  1986).  In  case  of  non-ideal  binary solvent  significant 
differences between the molecular duets take place. A solubility of solid substance in both 
types of solvents is calculated as Equation 18 (Ruckenstein and Shulgin I 2003):
         ƒS2 / ƒL2 (T, P) = x t2 γt2 (T, P, {x})                                                (Equation 18)
In this formula ƒ means fugacity for solid and liquid component, x means solubility and γ  
activity coefficients  in saturated solutions,  T and  P  represent  temperature  and pressure. 
Fugacity is also dependent on solubility and activity (Willams and Amidon II 1984). The 
dependence of solubility profile on pressure and temperature can be derived from the value 
of ideal solubility (Jouyban-Gharamaleki and Acree 1998).
4.2 Supercritical fluid process
Supercritical fluid process (SCF) is the technique based on dissolution of solid chemical 
substance in liquid existing in supercritical conditions (Van Hees et al 1999). Supercritical 
conditions mean that temperature and pressure are above the critical border. Having gas-
like diffusivity, viscosity and similar densities with common liquids they can achieve good 
mass transfer - thus poor-water soluble pharmaceutical compounds have opportunities to be 
dissolved.  Essential  parameters  of  this  method  -  temperature  and  pressure  can  be 
manipulated by using special  equipment.  Besides dissolution improvement,  supercritical 
fluid process is widely used in pharmaceutical practice for other purposes like dissolution 
particle size design and crystal engineering (Jung and Perrut 2001) and also production of 
micro-formulations (Perrut et al II 2005). Carbon dioxide is commonly used due to low 
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toxicity, cost and availability (Van Hees et al 1999). It has tendency to change condition 
rapidly into gaseous and thus is applied more commonly than such alternative supercritical 
solvents as higher alcohols, nitrogen dioxide (Jung and Perrut 2001) and trifluorometane or 
CHF3 (Roy et al 2007).
Before starting supercritical solvent method, it is necessary to know at least such data as 
polarizability  of  solvent  and  solute,  hydrogen  bonding  ability  or  range  of  interaction 
(Perera  2001).  The  densities  of  both  components  have  to  correlate  well  for  achieving 
successful result. The dissolution of solid substance is calculated according to Equation 19 
(Moneghini et al 2006):
dCr / dt = (kd A Vr) Cs                                                       (Equation 19)
where t means time,  Cr concentration and  Cs  solubility,  A contact surface area,  kd is the 
dissolution constant and Vr respectively volume.
Supercritical antisolvent dissolution may be applied in various techniques. The purpose of 
this  section  is  to  describe  the  most  common  of  them,  their  role  and  possibilities  in 
pharmaceutics.
4.2.1 Rapid expansion of supercritical solution (RESS) 
This method is based on rapid nucleation of substance dissolved in the supercritical fluid by 
forming of reduced-size particles (Jung and Perrut 2001). High pressure and temperature 
must be maintained in order to allow nucleation throw nozzle. The apparatus used in this 
technique consists of extraction and precipitation units (Figure 5). In the first one pumping 
of  pure  supercritical  liquid  under  desired  pressure  and speed to  heating  machine  takes 
place. Then fluid continues own movement to the area of machine where solid substance is 
situated. Active pharmaceutical solid may exist there both in powder and in dissolved form. 
A result  of  interaction  is  supercritical  solution  formation.  In  the next  step supercritical 
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liquid  moves  towards  the  precipitation  unit  of  this  type  equipment.  Finally it  nucleates 
throw the heated nozzle.
Figure 5. Construction of RESS-apparatus (Jung and Perrut 2001).
This sort of SFC is capable of production of fine particles and it can obtain narrow size 
distribution if parameters and equipment are chosen correctly.  For improvement of final 
result one may use co-solvent for avoidance of agglomeration. With respect to problems 
and weaknesses,  most  of  RESS-apparatus  have several  nozzles  and this  has a  negative 
effect on the final size distribution. Single-nozzle system produces better particles but has 
poorer  productivity.  Limited  dissolution  of  solid  substances  has  proven to  be the  most 
significant problem and requires additional costs.
4.2.2 Supercritical antisolvent (SAS) and gas antisolvent (GAS)
This technique is most used in the area of pharmaceutical supercritical fluids. The fluid in a 
form of liquid (in SAS technique) or gas (in a GAS technique) acts as an antisolvent, which 
stimulates the dissolution process (Jung and Perrut 2001). Firstly,  antisolvent is pumped 
towards a special vessel and a process continues by mixing of it with the pharmaceutically 
active solution. The driving force in this process is expansion of liquid due to dissolution of 
gas or liquid into active substance solution. Due to smaller strength of expanded solvent a 
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supersaturated solution is formed, commonly by hydrogen bonding. Addition of dissolved 
pharmaceutical substance is performed also by pump which is located in the opposite side 
of the vessel. For achieving the best result tubes leading from pumping machine must be 
connected to the bottom of vessel. This system includes also a precipitator filled with a 
small  amount  of  solid  substance  solution.  Usually  adding  speed  of  both  solutions  is 
different, but the best result is achieved when equal amounts are pumped per a time unit. 
This factor provides faster diffusion and narrower particle size distribution.
This method has numerous applications. In one of them addition of pharmaceutical solution 
is performed by spraying into carbon dioxide. Nozzle is located in the site where contact of 
supercritical fluid takes place. The name of this technique is Aerosol Solvent Extraction 
Process  (ASES).  The  SEDS  or  Solution  Enhanced  Dispersion  by  Supercritical  Fluid 
consists of several steps: mixing of substances, supercritical fluid and hydrogen-bonding 
formation after mixture is sprayed. Additive high frequency waves are also known to be 
used for breaking of supercritical solution. Independently on addition method, all SAS and 
GAS equipments have similar working scheme which is represented in Figure 6.
Figure 6. Construction of SAS/GAS apparatus (Jung and Perrut 2001).
GAS/SAS method can be utilized for other purposes such as preparing of polymers and 
nanospheres. It is also capable for production of formulations in a large scale.
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4.2.3 Particles from gas-saturated solutions/suspensions (PGSS)
The basic principle of this supercritical fluid technique is high solubility of gases in the 
solids and liquids (Jung and Perrut 2001). Thus the first stage is solubilization of gaseous 
supercritical agent in melted or suspended substance. Afterwards spraying occurs through 
nozzle. Due to short contact time between phases mixing is usually achieved surprisingly 
well. It’s believed to be provided by acidic nature of most fluids. Alternative method for 
suspendation may be adding of solution containing active ingredient into the supercritical 
fluid and mixing with assistance of pressure. Emulsion may be also formed by adding of 
solid product directly into the gaseous phase. Independently on the way of preparation, the 
resultant  is  flow  of  solid  particles,  quality  of  which  is  controlled  by  such  factors  as 
temperature, pressure, geometry of nozzle and flow rate. The action principle of this vehicle 
is shown in the Figure 7.
Figure 7. Construction of PGSS apparatus (Jung and Perrut 2001).
Like other supercritical fluid techniques, this method has many modifications, which apply 
different ways of mixing. There are portable machines for PGSS. Despite of simplicity the 
use of PGSS is limited due to high cost of apparatus.
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4.3 Salts
This  method  of  aqueous  solubility  improvement  is  very  old  and  widely  used.  The 
advantage is simplicity compared to alternatives. It's also possible to improve physical and 
chemical stability by salt manipulation. Their enhancement commonly leads to improved 
solubility  in water.  Pharmaceutical  salt  occurs always  as a molecular  complex of weak 
acidic  or  alkali  component  (pharmaceutical  active  ingredient)  and  strong  one.  Salt 
formation  requires  ionization  of  both  compounds,  which  takes  place  in  solution. 
Pharmaceutical salt must be stable, non-hygroscopic and dissolve well when it's formulated 
as a solid dosage form. 
4.3.1 Salt formatting principles 
For  predicting  salt  formatting  ability  one  needs  knowledge  about  physicochemical 
properties of cation and anion effect on solubility. Both salt forming compounds are chosen 
according to pKa values, which ideally must be similar (Gould 1986). In practice the most 
stable salt is formed when difference in this parameter is not more than 3 units (Bastin et al 
2000). Based on the fact  that  salt formatting agents are not neutral,  solution must have 
acceptable pH-value. Maximum solubility for each salt is observed at a pH-value, which is 
denoted as pHmax. This parameter gives information about ability or disability of substance 
to salt production (Serajuddin 2007). To make salt of basic substance pH value of solution 
must  be  smaller  than  the  maximum  value  until  process  is  over.  This  requirement  is 
explained by agglomeration and following sedimentation risks. Data about  pHmax help to 
predict stability of the final product. Each salt has own value of pHmax which is calculated 
using Equation 20: 
pHmax  = pKa + log([Bs ]/ √Ksp)                  (Equation 20)
There Ksp represents solubility factor and Bs intrinsic solubility which is derived from total 
solubility formula of basic salt as it's represented in Equation 21 (Serajuddin 2007):
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                        ST (salt) = [BH+](1+10 pH-pKa)                                                      (Equation 21) 
This law helps to validate the best conditions for salt formatting in cases of weak alkali 
drug. The value of maximum pH is important but not critical, Degradation of product can 
occur also in the lower acidity or basicity. This parameter is variable because salt can be 
formed in organic solution. The non-polar molecules can change this parameter radically 
both  by  increasing  and  by  decreasing  effect.  In  case  of  alkali  components  intrinsic 
solubility is shown to have tendency to increase in organic phase. This phenomenon leads 
to increased pHmax  value (Kramer and Flynn 1972). 
4.3.2 Salt choice and stability
In addition to dissolution behaviour, components for salt formatting should be chosen by 
their physiological and toxicological profiles, they have to be safe and easily available for 
human organism.  Pharmaceutically acceptable  salt  must  have low  pHmax and  pKa values 
(Gould  1986).  Theoretically  the  best  compounds  are  salts  of  inorganic  acids,  most 
preferable  being "physiological"  hydrochloride  (HCl),  but  there  are  numerous  problems 
limiting their usage. One of these is very high hygroscopy.  This is typical  for all  well-
soluble  salts  due  to  numerous  hydrogen-bonding  sites.  There  takes  place  humidity 
accumulation from atmosphere and also from excipients existing in formulation. Further 
this process leads to formation of less-soluble or insoluble hydrate. The problem can be 
solved by using of hydrophobic contents.
Due to  fact  that  salt  formatting  leads  to  the  change  of  crystalline  lattice,  variations  in 
melting point are also common (Bastin et al 2000). The range of melting variation may be 
in some cases 50-100 °C. Usually such great difference leads to instability during storage, 
which results is plastic deformation with following decrease of solubility parameters. This 
phenomenon is explained by modification of liquid layer above molecular complex and is a 
very common at conditions below the normal melting point. (Gould et al 1986) 
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4.4 Excipients
In numerous formulations water solubility and bioavailability are improved by addition of 
different  pharmaceutical  excipients.  They  are  acting  by  various  mechanisms  achieving 
favourable conditions and prevention of degradation.  Soluble and insoluble matrices are 
also  made  from  excipients.  The  main  condition  is  an  ability  of  substance  to  affect 
physicochemical  parameters  under  different  conditions:  during  formulation,  industrial 
production,  storage and dissolution in a human organism.  The most  relevant  method to 
measure an effect of excipients on bioavailability is  a comparison of dissolution per time 
unit  and  measurement  of  dissolution  rate.  These  parameters  are  shown  to  be  strongly 
dependent on properties and characteristics of current dosage form.
4.4.1 Prevention of degradation
Numerous pharmaceutically active substances dissolve better in anhydrous form than their 
hydrates. Hydration is well known to occur during manufacturing processes and storage. 
Hydration-preventing  substances  are  commonly  used  in  formulations.  In  case  of  liquid 
granulation - general way of moisture uptake during production - some agents are shown to 
prevent or at least to slow a rate of hydration process (Airaksinen et al 2003). They act as 
inhibitors and their effectiveness is dependent on such factors as relative moisture, amount 
of  water  molecules  around  system  and  moisture  reaching  kinetics.  For  example 
polyvinylpyrrolidone (PVP) works as a competitor against water molecules keeping thus 
formation of hydrate (Kesavan and Peck 1996). The mechanism of competition is based on 
amorphous  crystalline  structure  of  this  substance.  As an alternative  substance  one may 
apply a  silicified  microcrystalline  cellulose  (SMCC),  which  has  a  lower  water-sorption 
profile  than  the  original  molecule  –  microcrystalline  cellulose  (MCC).  The  last  one  is 
known to be the main source of water in process of hydration (Luukkonen et al 2001). This 
property is  based on molecular  structure of MCC and it´s  derivate.  MCC has a porous 
structure and the number of pores increases relatively to enhancement of humidity. Thus 
water  molecules  have  easier  way  to  penetrate  inside  and  construct  hydrogen-bond 
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interactions  with  free  hydroxyl  groups  of  polymer  chains.  Being  derivate  of 
microcrystalline cellulose, SMCC has also ability to intake water but SiO2-chains situated 
on the surface of this molecule are able to be hydrolysed with water molecules and thus to 
act as a reservoir (Kachrimanis et al 2006). Further water penetration in the crystalline site 
is  prevented  and  therefore  hydrate  formation  of  pharmaceutically  active  ingredient  is 
inhibited. This property may be used also during storage of product because this substance 
is widely used in a pharmaceutical practice based on better properties compared to MCC.
4.4.2 Release conditions manipulation
Another role of pharmaceutical excipients is to improve conditions for solubility process. 
By those conditions are commonly meant relevant acidity or basicity for compounds having 
pH-dependent solubility profile. Buffers are commonly applied for maintaining a pH-value 
in liquid formulations (Fokkens and De Blaey 1984). Most of oral dosage forms are solid 
and they must contain excipients which are able to create needed conditions in the GI-tract 
(Shaw et al 2005). This means manipulating of pH-value above the pKa which allows rapid 
dissolution  and following absorption.  The  most  appropriate  agents  for  this  purpose  are 
different  non-organic  salts  such as  bicarbonates,  chlorides  of  potassium and sodium or 
alternatively weak acids: acetic, tartaric, phosphoric etc. Criteria of choice are good water 
solubility and low chemical degradation with hydrolysis (Hirakura et al 2006).
4.4.3 Solid dispersions
The  alternative  method  to  improve  aqueous  dissolution  of  poorly-soluble  drug  is  a 
formulation  of  solid  dispersion which is  known to be a  system consisting of  drug and 
excipients (Shanbhag et al 2008). This sort of system may be produced by different ways: 
melting,  extrusion-spheronesation or direct  compression of matrix.  The last one is most 
common. For formation of solid dispersion matrices hydrophilic substances are used such 
as Polyethylene Glycol (PEG), PVP, hydroxymetyhlcellulose (HPMC) or chitosan (Asada 
et  al  2004).  Thus  this  type  of  system  contains  a  pharmaceutical  active  ingredient  in 
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combination with one or several excipients having maintaining stability properties in the 
aqueous media.  They are  validated  by their  solubility  properties  in  carrier  and also by 
ability  to  maintain  system  stability  (Shanbhag  et  al  2008).  For  improvement  of  water 
contact and plastic parameters surfactants may also be added into the solid dispersion. In 
these systems Tween 80, Docusate sodium and sodium lauryl suflate (SLS) are commonly 
used.  The  surfactants  are  preferably  solid  or  semisolid  since  this  affects  their  stability 
maintaining ability (Ghebremeskel et al 2007). Release of pharmaceutical active compound 
from solid  dispersion  can  occur  in  several  ways.  The  first  one  is  based  on  change  of 
crystalline form from regular into amorphous and in the second one a molecular dispersion 
of  drug  takes  place.  Independently  on  the  liberation  way  the  presence  of  surfactants 
enhances noticeably this process. Another factor, which has a major effect on speed is a 
ratio of active compound to diluent (Furlanetto el al 2006).  Molecular weight of matrix 
builder  has also a major  effect  on dissolution properties  (Moneghini  et  al  2006).  Light 
substances are able to provide both thicker layer for diffusion and also adequate particle 
size  distribution.  Application  of  solid  dispersions  makes  possible  to  avoid  moisture 
degradation  of  both  active  compounds  and such common pharmaceutical  excipients  as 
starch, lactose or microcrystalline cellulose. They are widely used in various formulations 
and  can  achieve  rapid  dissolution  profiles.  Alternatively,  an  adding  of  hydrophobic 
compound  as  a  base  of  matrix  is  also  possible.  Ethylcellulose  (EC)  may  represent  an 
excellent  example  of  such  builder  (Neau  et  al  1999).  Hydrophobic  matrices  help  in 
achievement  of  needed  aqueous  dissolution  parameters  by  molecular  relaxation  during 
contact with the water phase. Thus they form a diffusion pathway. This method is used 
mainly for high-loaded tablets, which need slow liberation. 
4.5 Cyclodextrins
These molecular complexes are described as a family of crystalline, non-hydroscopic and 
homogenous  cyclic  oligosaccharides  consisting of  at  least  six  glucose  rings  attached 
together by ether bonds (Szejtli  1998). They form two-sided molecular complex  having 
hydroxyl  groups on the core and saccharide-substituents inside (Bounaceur et  al  2007). 
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Thus the external  part  is  hydrophilic  and cavity has hydrophobic  properties  (Figure 8). 
Cyclodextrins have a cone form  by a three-dimensional view.  This  sort of molecules  is 
classified as three major groups depending on the number of saccharide units. These are α- 
(6 units), β- (7 units) and γ-cyclodextrins (8 units). All natural cyclodextrins are products of 
starch  enzymatic  degradation,  which occurs  in  micro-organisms,  commonly  in Bacillus  
macerans  bacteria  (Van Hees  et  al  1999).  There  are  also synthetic  derivatives such as 
methylated or acetylated molecular complexes (Szejtli 1998). This type of  substitution is 
usually used for enhancement  of lipophilic  character  of molecules and improvement  of 
bioavailability.
According to  different number  of  monomer  units  in  molecular  structure  three common 
cyclodextrin families differ by physicochemical properties (Szejtli 1998). Relatively poor 
water-solubility  of  β-cyclodextrin  compared  to  other  ones  is  explained  by  neighbour-
situated  hydroxyl  groups  in  the  exterior  site.  This gives possibility  for  intra-molecular 
hydrogen  bonding.  According  to experience,  β-cyclodextrins  are  most  appropriate  for 
pharmaceutical practice. For improvement of water solubility properties they use several 
synthetic  forms  like  2-hydroxypropyl-β-cyclodextrin  (HPβCD),  which  is  a  product  of 
polymerization with propylene oxide (Brewster and Loftsson 2002).
Figure 8. Common structure of cyclodextrin (Bounaceur et al 2007). 
Due to hydrophobic cavity  cyclodextrins  are able  to  easily make complexes  with other 
hydrophobic molecules maintained by non-covalent interactions like Van deer Waals. This 
phenomenon  is  widely  utilized  in  the  pharmaceutical  practice  and  cyclodextrins  are 
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commonly used to  enhance water-solubility  of  numerous  compounds.  Other application 
areas of cyclodextrins are improvement of bioavailability, stability and also target-dosage 
(Brewster and Loftsson 2002).  These molecules may be used as well  as excipients  and 
matrices for solid dispersion systems (Pina and Vegia 2000). 
Construction of two-sided complex is not always simple and often requires optimization of 
conditions  such  as temperature  and  pressure  (Bounaceur  et  al  2007).  Synthesis  of 
cyclodextrins needs usually grinding of components for achieving better result. Especially 
it's actual when process occurs in the aqueous conditions. This technique is utilized to solve 
a  problem of  broad particle  size.  Another  factor  limiting  water  use  is  the hydrophobic 
nature of many pharmaceutical  compounds and  construction of  molecular complex with 
cyclodextrine often takes place in binary solvents or supercritical fluids (Van Hees et al 
1999). 
For utilizing this technique addition of water is essential. It allows formation of interaction 
site due to partial or total core dissolution. Ways of aqueous adding may be different and 
take place both by dissolution of pharmaceutically active compound or by addition of API 
into water-cyclodextrin solution (Bounaceur et al 2007). The first  method is preferable  - 
aqueous molecules escape due to increase of temperature. Elimination of water is followed 
by replacement of  liquid state by solid. The next step is adjustment of temperature and 
pressure  to  the  needed  level.  The molecular  complex  forms and  further  dissolves. 
Temperature, pressure, density of solution and molar ratio have a great effect on success of 
this procedure. Thus increase in pressure  allows improvement of solubility according to 
enhanced molecular interaction (Van Hees et al 1999). Change of temperature achieves a 
similar result. The increase of water content often has a curative effect  due to increase of 
total volume of physical mixture. Thus cyclodextrin cores have better ability for hydrogen 
bonding and further partial dissolving (Bounaceur et al 2007). Same effect can be achieved 
with increase of density as well as of molar and mass ratios. 
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Cyclodextrins  have a great ability to  enhance solubility of neutral compounds. However 
their application to ionized medicines or common salt forms is limited by surface properties 
and  possible  chemical  degradation  (Carrier  2007).  Utilization of  cyclodexitrins  is  also 
limited with high cost compared to other chemicals.
4.6 Solid state manipulation
Methods based on crystal lattice manipulation are widely used for enhancement of aqueous 
solubility.  These techniques are divided  into  three  main  sub-methods:  polymorphic, 
pseudopolymorphic transition and co-crystallization. 
4.6.1 Pseudopolymorphic transition
The most  common pseudopolymorphic  transitions of  crystalline  state  take  place  during 
contact  with  water  when formation  of  hydrate  or  solvate  occurs.  The  simplest  way of 
avoidance of this phenomenon is storage of solid pharmaceutical compound in non-humid 
air having suitable temperature range (Pirttimäki and Laine 1994). Appropriate conditions 
must be ensured during manufacturing process. If  solid state has  been  hydrated the best 
way of converting back into anhydrous one is water removal. A reliable method is heating 
of compound. This process may be done in oven, but use of hot gases as nitrogen is also 
possible (Duddu  et  al  1995).  To  achieve  contact  with  solid  state  and  further  rapid 
evaporation of water both flow rate and temperature of gas must be adjusted correctly. 
Dehydration may be performed also by chemicals  and  alternatively  by manipulating  of 
hydrate's physical properties. Some excipients, which are able to intake water into the core 
can  also  be  applied  in various  formulations  both  during  production and  storage.  As  a 
thermodynamic phenomenon, dehydration requires activation energy and it depends on the 
particle size and sample weight (Agbada and York 1994). Decrease in particle size makes 
solid  better  available  for  interaction  with  heated  air.  As  the  result  there  is  noticeable 
reduction of activation energy and also decrease of heat during processing. Larger surface 
area can also be achieved by putting a greater sample  mass into dehydration equipment. 
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This method can have a problem of self-cooling and slow escape of aqueous molecules. It 
can be solved by maintaining constant heat during process of dehydration.
Such common technique of solubility enhancement as binary solvents is also available for 
dehydration purpose (Zhu et al 1996). It depends on such factors as thermodynamic activity 
a, which has different values both for hydrate and anhydrous form. Dehydration in binary 
solvent media is predictable by the way represented as the Equation 22:
Kh = a [H2O]-m                                                                 (Equation 22)
Where  Kh  is  equilibrium constant  of process and symbol  m represents number  of water 
moles taken by crystalline solid. For phase transition activity current value of anhydrate is 
shown to be less  than  similar  of  hydrate.  Manipulation  of  binary solvent  requires  also 
knowledge of such essential  variable as water activity (aw), which is strongly dependent 
both on activity coefficient  (xw)  and aqueous molar  fraction (γw).  When  values of those 
parameters  are  clear  one can  change mixture  contain  to  such which  is  able  to  prevent 
hydrate formation or at least make dehydration possible. On the other hand organic phase 
exists  in  this  system  as  an  activity  lowering  factor  and  must  not  dissolve  any  solid 
compound for achievement of final success. 
4.6.2 Crystalline structure modification
The  goal  of  this  technique  is  to  change  crystalline  form  of  pharmaceutically  active 
compound into another one. Commonly the objective is to get the most thermodynamically 
stable polymorphic form or such crystalline structure, which does not revert during storage 
in  the room temperature.  Thus polymorphic  form has to possess a  low value of fusion 
enthalpy,  which  is  measured  as  a  Gibbs  free  energy  against  the  absolute  temperature 
(Henck and Kuhnert-Brandstatter 1999). These data provide  opportunities  to estimate the 
needed  phase transition  temperature  regimen. Another  parameter  characterizing  a  stable 
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form is density.  According to the density rule, stable crystalline lattice has greater value in 
the absolute temperature compared to the unstable one.   
Commonly phase transition of polymorph takes place without presence of any liquid or 
vapour  and thus this  process is  named solid-state  transition (Vippagunta et  al  2001).  It 
occurs in four steps: molecular loosening and bonding breakage, formation of intermediate 
solid, nucleation of new solid phase and growth of the last one into a new form. Transition 
process  is  thermodynamic  and  thus  requires  heat  for  bond  breakage  and  following 
rearrangement.  A phase change starts at  transition temperature or value of phase convert 
beginning. Temperature is also a critical factor in case of polymorph transition (Airaksinen 
et al 2004). Alternatively polymorphic form change may take place in aqueous conditions, 
for example  during wet granulation  and also  in  dissolution tests.  In these cases critical 
factors are solubility, solvent polarity, viscosity and solution concentration (Getsioan et al 
2008).  Existence of substance  as different polymorphs is assessed by different  analytical 
techniques such as NIR-spectroscopy, Raman spectroscopy or or X-Ray diffractometry.
Production  of  stable  form  is  widely  used  in  pharmaceutical  practice.  The  problem  of 
hygroscopity is often solved by this technique and also production of more stable solid 
formulations  becomes  possible.  The  solubility  profile  of  the  most  stable  form is  often 
inferior compared to the metastable one. Development in this area aims at  production of 
lattices which are resistant to room temperature and exist as energetically more favourable 
metastable polymorph.
4.6.3 Co-crystals
An  alternative  approach  to  improvement  of  stability,  solubility  and  bioavailability  is 
utilization of technique named as crystal engineering. By this term is meant modification of 
crystalline  form  in  the  solid  state.  The  most  predictable  resultant  of  this  process  is 
formation of co-crystal or complex consisting of two or more neutral molecules which exist 
as united crystalline lattice. Commonly one of them is pharmaceutically active and another 
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is guest molecule, but there are also known numerous cases when both of components are 
APIs. Co-crystal always exists as a solid in room temperature conditions (Almarsson et al 
2004). Physical stability of this molecular complex is ensured by powers, which have to be 
non-covalent  and  directional.  In  most  cases  hydrogen  bonding  is  the predominant 
maintaining  interaction  due  to  its  directional  and  robust  nature  (Trask  et  al  2006). 
Alternatively there can be detected such types of intermolecular bonds as Van deer Waals 
or ionic  one (Almarsson et al 2004). This technique is suitable for numerous molecules, 
also for neutral ones.
Before  construction  of co-crystal one  needs  to  know  the  molecular  structure  of  both 
compounds used in this process. The most important conditions are presence of sites which 
have ability to accept and donate hydrogen bonds and an appropriate molecular geometry. 
The latter means different conformations which have ability to ensure formation of strong 
and  stable  complexes  (Almarsson  et  al  2004).  Because  many  of  co-crystallization 
compounds  exist  as  ionisable  molecules  information  about  their  pKa-values  is  often 
essential (Remenar et al 2003). For achieving acceptable stability level the difference in this 
parameter must be less than 2 units. This rule is especially important in case when acid and 
base are forming co-crystal and it can be utilized for further dissolution in water medium. 
There are several ways of co-crystallization based on various techniques. Most of them take 
place in liquid and thus require dissolution of all solid compounds. Solvates and solutions 
must be chosen correctly  according to physicochemical data. Thus both solid substances 
must  have similar  dissolution  profiles  and media  must  dissolve  them well  (Trask et  al 
2005). Particle size has a major role in this case and compounds must be milled beforehand. 
The first way of co-crystal preparing is a slow evaporation of saturated solution. Nowadays 
grinding of crystalline substances in solution is also widely used (Chiarella et al 2007). This 
method always starts from dissolution of all compounds in their own vessel and the next 
step is mixing  with special equipment (Trask et al 2005). Alternatively one of solutions 
may be dropped into another and thus the technique is named as solvent-drop grinding. The 
advantage  of  this  method  is  possibility  of  crystal  growth  and  polymorphism  control. 
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Alternatively co-crystals  may be prepared in dry conditions.  Grinding is  possible  when 
compounds are milled manually with mortal in pestle or automatically in mixer and drops 
of liquid catalyst can be added (Trask et al 2005). Sometimes co-crystals are prepared by 
heat, microwaves and pressure (Zawarotko 2007).
Usually co-crystals differ from parent molecules by their physicochemical properties. For 
example melting point of new lattice has a value, which is smaller than that of original ones 
(Childs et al 2004). This  phenomenon  is explained by different molecular configuration. 
Stability is often improved by co-crystallization and thus these complexes are less sensitive 
to such a common problem as hydration (Hickey et al 2007). Aqueous solubility is almost 
always improved or at least  it remains  on the same level. Co-crystal is more stable than 
amorphous substance and thus it has more advantages in pharmaceuticals. But there is  a 
risk of recrystallization. 
Another advantages of co-crystallization compared to older physicochemical enhancement 
methods such as salt formation, use of excipients, polymorph transformation are avoidance 
of  additional  cost,  shorter  processing  time  and  reduced  failure  risk.  For  example  salt 
formation is suitable only for ionisable molecules with appropriate  pKa-values while  co-
crystallization  works  also  with neutral  compounds.  In  case  of  excipients,  chemical 
imcompatibility is often a problem, which can be avoided with this innovative technique. 
Thanks to crystal engineering such risks as crystalline form degradation due to presence of 
surplus of binary solvents and application of  suprecritical fluid,  presence of inappropriate 
conditions for cyclodextrins  can be forgotten.  However  the weakness of this progressive 
technique is often slow processing and need for special expensive equipment. 
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5.  TECHNIQUES  USED  IN  SOLUBILITY  IMPROVEMENT  OF  XANTHINE 
DERIVATES
Previous  sections  presented common  principles  and  methods  used  for solubility 
improvement of poor water-soluble solid pharmaceutically active ingredients.  All of them 
must be validated with respect to to physicochemical properties of a particular chemical 
substance or at least to substances belonging to the same group. The aim of this part is to 
describe different techniques, which  are  commonly  applied for solubility enhancement  in 
case of natural xanthine derivates. 
5.1 Theophylline
All xanthine derivates are weak bases and theophylline also has a slight ampholytic nature. 
Thus it  has ability to  ionise  in  suitable  conditions  and further  dissolve.  In  case of this 
substance the best dissolution profile is achieved  in basic  environment. Thus dissolution 
intermedia must  have suitable  pH-values (Fokkens and De Blaey 1984). Decrease of  pH 
impairs  solubility  profile  of weak alkali  pharmaceutical  agents  (Nelson 1957).  Because 
theophylline  is  usually  administrated  per-orally,  substances  which  have  potential  to 
maintain or create current conditions are needed. In case of liquid formulations the best 
choice is addition of basic buffer like sodium hydroxide, but its high toxicity is the main 
limiting  factor.  Such  combinations  as  phosphates  and  chlorides  are  known  to  be an 
excellent alternative for achievement of theophylline's good dissolution profile. 
Presence of some salts in addition to buffer agents can  have strong effect on  dissolution 
(Al-Maaieh  and  Flanagan  2002).  This  phenomenon  is  divided  in  two  components  - 
kosmotropity and chaotropity. The first term is described as improvement of polarizeability 
and  by  the  second  is  meant water-structure  breaking.  Commonly  double-charged  ions 
belong to the first group and the single-charged to the second one. Some chaotropes as 
NaClO4 and  NaSCN  are  able  to  improve  the  dissolution  profile  of  theophylline.  The 
mechanism of this phenomenon is based on ability of salt to reduce intramolecular energy 
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making  thus  water molecules  more available  for interaction.  Such type  of  salts  may be 
successfully added as solubility improvement excipients into solid oral dosage forms.
But the most common way is still formation going through ionisation. This process gives 
more stable results and  it  is not concentration-dependent unlike the previous one. There 
also can be needed a smaller volume for tabletting or granulation procedure when medicine 
is used as a salt form compared to addition of solubility increasing agents. This tendency is 
well-known for theophylline - various salts of this pharmaceutical ingredient are widely 
applied  both in  the  manufacturing  and  formulation  processes  (Nelson  1957).  Another 
important advantage of theophylline salt formation is enhanced solubility in gastric fluid 
compared to the pure substance. This phenomenon is well certified by test performed in an 
acidic  medium.  Aqueous solubility  is  shown to  have  same  tendency  due  to  increased 
ionisability. Each salt has own dissolution profile and thus bioavailability. The last one can 
be evaluated by blood levels of the compound. Thus potassium salts  are known to  have 
commonly better profile compared to sodium ones. In case of special theophylline salts like 
choline one there has been noticed a higher dissolution rate. Apart from enhanced solubility 
effect salts provide also protection against pH-value changes. In case of theophylline salts 
improved solubility behaviour is  detected in the alkali  conditions. This phenomenon may 
be utilized for formulations of enteric dosage forms.
For  development  of  liquid  oral  dosage  forms  containing  theophylline  (suspension  or 
solution)  binary  solvents  may  be  used.  Such  widely  applied  co-solvent  in  laboratory 
practice  as  methanol  must  be  avoided  due  to  extremely  high  toxicity.  The  common 
assisting  solvents  used  in  such  type  of  formulations  are  ethanol,  different  glycols  of 
ethylene and also propylene (Vojnovic and Chicco 1997). The first step in this process is 
preparing of theophylline saturated solutions and in the next one planning of co-solvent 
volume ratio takes place. Most of pharmaceutical oral formulations include also various 
excipients and flavouring agents like sorbitol. These substances have also a major effect on 
bioavailability of the theophylline (Fassihi et al 1991). They can both increase and reduce 
this parameter.
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Binary solvents  may be applied  in  supercritical  fluid  technique  for aqueous dissolution 
enhancement  (Johannsen  and  Brunner  1995).  Addition  of  organic  compound  increases 
solubility of solid substance up to ten times compared to the pure carbon dioxide. Methanol 
can be used as a solvent, but SCF is a better alternative to this toxic alcohol (Roy et a 
2007). This technique demonstrates also ability to produce a better particle size distribution 
and thus provide improvement of dissolution profile. 
Excipients  used in pharmaceutical  solid oral  dosage forms play major role  in solubility 
manipulation. This property commonly belongs to disintegrants. As it's well known, rate 
and level  of  solubility  are  strongly dependent  on the  chosen substance  and its  amount 
(Gohil et al 2004). To achieve enhanced solubility of formulation consisting of insoluble or 
poorly soluble active substance a great concentration increase of excipient is required. An 
alternative  approach to  manipulate  dissolution  and  release  properties  of  dosage  unit  in 
various conditions is binder validation (Nunthanid et al 2004). A good example is chitosan, 
which dissolves well in acidic media and thus can be used in rapidly released theophylline 
formulations. In addition to disintegrant amount other affecting factors are known like type 
of  formulation,  manufacturing  way  and  storage  conditions.  Thus  theophylline  tablets 
compressed from granules have shown to have longer dissolution time compared to the 
directly compressed (Olmo and Ghaly 1998). This phenomenon is explained by decreased 
porosity  and  possible  gel  formation  in  formulations  made  by  granulation.  Another 
important factor is compression force. For achievement of suitable dissolution profile this 
parameter  must  be  relatively  small  because  otherwise  production  of  tablets  having 
enhanced density and decreased porosity takes place. Moisture during production process 
has also a noticeable effect due to powders ability to intake liquids (Hauschild and Picker-
Freyer 2006). All excipients differ in wetting ability and this problem can be solved by 
tablet coating. A care about storage conditions must also be taken since many polymers are 
known to be strongly hygroscopic (Wu and McGinity 2000). This is especially important 
for  films  consisting  of  plasticizers  maintained  by  hydrogen-bonding  sites.  Thus  water 
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intake has a great effect. The dissolution profiles of units kept in the high relative humidity 
can be different from those preserved in dry environment.
Numerous theophylline formulations are designed as solid dispersion matrices due to great 
advantages  of  this  form:  relatively  simple  production,  controlled  particle  size  and thus 
possibility  to  improve  dissolution  profiles.  In  the  process  of  theophylline  matrix 
formulation one must notice many factors. The first one is such a physicochemical property 
of polymers as pH-dissolution dependence (Ceballos et al 2005). Polymers, which dissolve 
independently on  pH-value of environment are a better alternative, but they're known to 
have  a  problem  of  swelling.  It  can  be  solved  by  polymer  mixing  in  different  ratios 
dependently on the formulation purpose and type. Dosage forms designed for immediate 
release  must  contain  a  bigger  ratio  of  pH-dependent  polymer,  for  sustained  release 
formulations pH-independent polymers are more favourable. An excellent example can be 
chitosan-based  theophylline  matrix  formulations  (Asada  et  al  2004).  Another  important 
factor affecting dissolution and release behaviour is hydrophilic or hydrophobic nature of 
the applied polymer (Furlanetto et al 2006). Thus matrices made from hydrophillic HPMC 
dissolve better in aqueous media, but there's also a noticeable dependence on the diluent to 
active substance ratio which has to be quite high in relation to conventional tablets.  
Theophylline-cyclodextrine matrices are also widely used in the pharmaceutical  practice 
(Pina and Veiga 2000). The most common technique in dispersion formation is grinding of 
compound. For successful production it is necessary to achieve conditions, which enable 
interactions of cyclodextrine with theophylline molecules (Wei et al 2003; Terekhova et al 
2007). One can use weakly acidic solution assisting interaction. A success of this procedure 
is  measured  by  decrease  in  temperature  which  is  well-noticeable  by  energy  profile. 
Dissolution is shown to be rapid due to favourable structure of formed molecular complex 
(Pina and Vega 2000).
Manipulation  of both polymorphic  and pseudopolymorphic solid  states is  also common 
technique used in solubility or at least stability improvement of theophylline. As it's well 
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known anhydrous theophylline dissolves much better  compared to monohydrate and the 
last one is known to form easily in the presence of moisture. The most common way used 
in  pseudopolymorphic  changes  is  dehydration  through  drying  of  hydrate.  The  best 
dehydration kinetics were achieved in relatively high temperatures (Otsuka and Kaneniwa 
1988). When the constant heat value is 80 ºC water can evaporate more rapidly compared 
to  lower  temperatures.  Maintenance  of  this  range  is  shown to  be  the  best  way to  get 
anhydrous form. Such factors as particle size and surface area have effect on the final result 
of this process. For preventing of hydration during wet granulation and pelletization, α-
lactose monohydrate (Airaksinen et al 2003) and pure microcrystalline cellulose must be 
avoided due to high hydrate formation risk (Herman et al 1988). Silicified microcrystalline 
cellulose has better  stabilization potential,  but practically it  delays  theophylline hydrous 
form formation (Airaksinen et al 2003). This substance is known to have better stability 
enhancement properties than pure cellulose and thus it has good experience in improvement 
of  dissolution  behaviour  of  solid  theophylline  oral  formulation  (Jørgensen  et  al  2004). 
Increased amounts of PVP are shown to prevent formation of hydrate (Kesavan and Peck 
1996).
Because dehydration process requires heat, polymorphic transition of anhydrous form can 
occur during  this  procedure.  Anhydrous  theophylline  is  known  to  appear  as two 
polymorphs and also as a metastable form. The last one is known to have big value of free 
energy and thus supposed to be well-soluble (Phandis and Suryanaraynan 1997). It converts 
rapidly  to  the  stable  form  in  room  temperature  and  paradoxally,  also  during  heating. 
Another factor with strong effect on phase transition is high relative air humidity (Matsuo 
and Matsouka 2007a). Absorbed water is able to change molecular structure of metastable 
theophylline. Thus the biggest challenge is to design a procedure allowing maintenance and 
stabilization of this advantageous structure.
Having hydrogen-bonding sites in the molecular structure, theophylline possesses ability to 
form co-crystals with numerous compounds (Trask et al 2006).  Additional advantage of 
this  molecule  for  new  lattices  production  is  occurrence  of  both  carbonyl  and  amine 
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functional  groups  (Childs  et  al  2007).  Thus ionization-crystallization  becomes  possible. 
New structures such as aminophylline containing theophylline may be also classified as 
salts.  Co-crystallization of theophylline  is  usually going through various  techniques  but 
commonly it requires stable humid conditions (Jayasankar et al 2007). It is based on poorer 
water-solubility profile affected by presence of water molecules in the crystalline lattice. 
Instability in high air relative humidity is known to be very common to ionized co-crystals 
due  to  possible  decomposition  into  original  compounds  and  further  hydration  in  the 
presence  of  aqueous  molecules.  (Trask  et  al  2006). Thus  the  best  choice  for  stability 
improvement  is  formation  of  combinations  consisting  of  theophylline  and  neutral 
compounds.  Another  problem  of  molecular  complexes  produced  through  ionization  is 
possible  poorer  water  solubility  compared  to  salts  (Childs  et  al  2007).  However  such 
systems are shown to be able to improve dissolution rate due to rapid dissociation. 
5.2 Caffeine
Similar techniques are applied for dissolution of caffeine and theophylline because these 
molecules  are  related.  Since  caffeine  dissolves  better  in  water  being  also  a  less-used 
substance  in  therapeutical  area,  use  of  diverse  techniques  is  not  justified  and does  not 
provide benefits. 
Like theophylline, caffeine has been shown to dissolve well in basic binary solvent systems 
(Fokkens and De Blaey 1984). Due to better solubility potential, the need of binary solvent 
is  smaller.   This  technique  may  be  used  to  improve  solubility  of  this  agent  during 
dissolution  in  supercritical  solvent  system  (Kopcak  and  Mohamed  2005).  Addition  of 
ethanol was noticed to enhance solubility of caffeine in SCF compared to the pure CO2. 
This  phenomenon  is  based  on  additive  hydrogen  bonding  sites.  Increase  of  pressure 
improves also solubility of caffeine in supercritical fluids. 
In  cases  of  polymorphic  and pseudopolymorphic  crystal  lattice  changes  caffeine  shows 
same tendencies as theophylline (Kryzaniak et al 2007). Thus water loosening occurs at 
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temperature range 25 °C and RH 30%. Increase of temperature to 40 °C and decrease of 
relative humidity to 11% have positive effect on final result of this process. Phase transition 
of metastable form into stable one occurs similarly to theophylline: during heating, storage 
in room temperature and in increased humidity. All of them are based directly on the same 
effect. Anhydrous caffeine is known to be an unacceptable pharmaceutical form and thus 
co-crystallization  is  a  better  alternative  (Trask et  al  2004).  Making common crystalline 
lattices  with  acids  improves  humidity  resistance.  As  the  resultt  water  solubility  also 
increases.
6. THE AIM OF THIS STUDY
The aim of this study was to improve bioavailability of such natural xanthine derivates as 
theobromine and theophylline that were chosen as model drugs. The first one was chosen 
due to extremely poor solubility profile and the second one due to hydration sensitivity. 
Caffeine was used as a third compound in this work. A target was solubility improvement 
or at least stabilization of this parameter on an acceptable level. Crystal engineering was 
applied as the general method to produce co-crystals or alternative complexes constructed 
by intra-molecular  interactions.  This  study was  divided  in  two parts.  Firstly,  solubility 
profile  of each xanthine derivate  was checked under different  temperature  regiments  in 
such various liquids as water, organic liquids and binary solvents. In addition to these test, 
work also included selection of most appropriate method for solid-state manipulations in 
further  tests.  The  second  part  included  solid  state  manipulation  of  theophylline  with 
carboxylic  acids  and  HPMC  performed  by  ball  milling  technique,  check  of  hydration 
resistance  ability  of  the  achieved  complexes  by  wet  granulation  and  storage  in  humid 
conditions.  Solubility  profile  of  produced  complexes  was  measured  with  utilization  of 
intrinsic dissolution.
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7. MATERIALS AND METHODS
7.1 Pre-tests in solubility
In this series of tests and also in all following experiments anhydrous forms of theobromine 
(Synopharm  GmbH,  Germany),  theophylline  (600451AX10,  BASF  Ahtiengesells  chaft 
GmbH, Ludwigshafen, Germany) and caffeine (86/10-2004/10, Oriola OY, Finland) were 
used. In determination of aqueous solubility distilled water was used as intermedia. For 
solubility  tests  in  organic  phase  ethanol  (Finland),  methanol  (2902LC,  Sigma-Aldrikh 
GmbH,  Germany),  1-propanol  (13130,  Sigma-Aldrikh  GmbH,  Germany),  2-propanol 
(RH1018,  Rathburn  Chemicals  Ltd,  Scottland),  acetone  (1465,  Sigma-Aldrikh  GmbH, 
Germany) were applied as well as their water binary solvents (w/w) prepared in relation 
50%.  Hydrochloric  acid  37%  (Riede  de  Häen,  RdH  Laborchemikalien  GmbH&Co, 
Germany) was used in pH-solubility tests.
Preparation of binary solvents was started with weighing of both water and organic phases 
in amount of 125 g. This procedure was performed in decanter glasses of volume 250 ml 
(Scott  Garan,  Germany)  by  Sartorius  CP3202P  (Germany)  balance.  Afterwards  both 
liquids were moved into 500 ml glass bottles (Finland) and mixed during 15 minutes on 
heating plate (IKA Werhe, RCT Basic Germany) in constant temperature regimen. Mixing 
was assisted with magnet mixer at rotation speed 600 rpm. 
All solid samples were placed in weighing paper and mass was measured by Mettler Toledo 
AX 105 (Taiwan) balance. Further, powders were moved into glass tubes (Laborexin OY 
Finland).  In the next step liquid phase was added by pipettes  of volume 1,  5,  10 (EM 
Hirschmann  Germany)  and  25  ml  (E-Mil  England).  Dissolution  process  took  place  on 
heating  plate  (IKA  Werhe,  RCT Basic  Germany)  with  assistance  of  magnet  mixer  at 
rotation speed 340 rpm. Solubility pre-tests of xanthines in all liquid environments were 
carried out visually in three temperature ranges – 25, 40 and 60 ºC. Temperature of solvent 
was measured by thermometers (max 110 ºC, Germany). The only exclusion was acetone, 
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which has relatively low boiling point and for this reason it wasn’t heated to 60 ºC (Table 
4). This temperature regimen was applied to binary solvent of this liquid with modified 
physicochemical properties. Tests for theophylline and caffeine in organic phase were also 
done only in 25 ºC according to their high solubility profiles. In all experiments liquids 
were added slowly into glasses until solid sample was shown to be dissolved. In addition to 
these experiments solubility of xanthines was tested in boiling water environment. They 
were weighed by Sartorius CP3202P (Germany) balance and weighing paper; theobromine 
and theophylline were in amount of 1 gram and mass of caffeine was equal to 2 grams. 
Afterwards initial water volume of 10 ml was added by analytical pipette of 10 ml (EM 
Hirschmann Germany) into decanter glass of volume 100 ml (Scott Garan, Germany) with 
thermometer (max 110 ºC, Germany), glass was moved to heating plate (IKA Werhe, RCT 
Basic  Germany)  and  heated  to  boiling.  Temperature  regimen  was  recorded.  Each 
compound was added into decanter with spattel and used mass was measured by calculating 
residual  after  weighing.  If  needed,  water  was  added  by  pipette  of  volume  5  ml  (EM 
Hirschmann Germany). This procedure continued until total dissolution. 
Table 4. Physicochemical properties of liquids used in organic dissolution tests.
Sample Structure
formula
Molecular
mass (g/mol)
Boiling point
(ºC)
Density
(g/cm3)
Ethanol C2H5OH 46.07 78.37 0.789
Methanol CH3OH 32.04 64.70 0.787
1-Propanol C3H7OH 60.09 97.10 0.803
Isopropanol C3H7OH 60.09 82.30 0.790
Acetone CH3COCH3 58.09 56.53 0.790
Mass of theobromine used for aqueous solubility measurement in room temperature was 
52.76  milligrams.  According  to  poor  dissolution  profile  also  in  higher  temperatures, 
samples of 25.75 mg (40ºC) and 25.80 mg (60ºC) were used. Approximately similar mass 
of theophylline (25.19 mg) was used for solubility measurement in 25 ºC water. Due to 
good solubility  profile  in  higher  temperature  regimens  greater  amounts  of  theophylline 
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were used: 75.23 and 75.46 mg samples. Caffeine was weighed in such masses as 100.51 
mg, 100.55 mg and 100.44 mg for all temperature regimens. Data about amounts used in 
test performed in organic and binary phases is represented in Table 5. The pH-dependent 
solubility was checked only for theobromine in mass of 50.76 mg and the value of this 
quantity was measured by indicator paper (Finland).
Table 5. Amounts of xanthines used in solubility measurement in organic and binary 
solvent phases. TB  = Theobromine, TP = Theophylline, CAF = Caffeine.
Solvent used Sample mass (mg) for 
measurement in 25 °C
Sample mass (mg) for 
measurement in (TB only)
TB TP CAF 40 °C 60 °C
Ethanol 25.62 75.26 50.55 10.84 10.84
Methanol 25.88 75.23 50.81 10.42 10.42
1-propanol 25.14 75.18 50.45 10.46 10.46
2-propanol 25.04 75.91 50.12 10.40 10.40
Acetone 25.12 75.30 50.66 10.61 10.61
Ethanol:water 50% (w/w) 25.45 75.44 25.23 10.63 10.31
Methanol:water 50% (w/w) 25.47 75.89 25.63 10.77 10.21
1-propanol:water 50% (w/w) 25.62 75.46 25.30 10.76 10.13
Isopropanol:water 50%   (w/w) 25.54 75.49 25.54 10.71 10.49
Acetone:water 50% (w/w) 25.37 75.30 25.05 10.69 10.18
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7.2 Crystal engineering
7.2.1 Slow evaporation
A co-crystallization  of theobromine with theophylline  and caffeine was tried with slow 
evaporation method. Due to insufficient results produced during solubility tests in organic 
liquids  and  also  in  binary  solvents,  boiling  water  was  chosen  as  crystallization 
environment. Each xanthine was weighed in the Sartorius CP3202P (Germany) balance in 
mass of theobromine and theophylline equal to 1 gram and caffeine was used in amount of 
2 grams. Next, distilled water was added by measuring glass of volume 50 ml (Hirschmann, 
Germany) into decanter of volume 250 ml (Scott Garan, Germany), moved to heating plate 
(IKA Werhe, RCT Basic Germany) and heated.  Thermometer (max 110 ºC, Germany) was 
inserted in vessel and temperature was followed and recorded. Theobromine was added by 
spattel until supersaturated solution was formed and later same procedure was done with 
theophylline and caffeine. Addition of powders was also performed step by step until there 
occurred formation of supersaturated solution. Mass of used solid substance was measured 
by residual  method after  weighing.  Each substance was dissolved in own vessel,  when 
process was performed contents of both decanters were mixed together in the same glass. 
Then  flask  was  covered  by folio  with  holes  and allowed  to  cool  in  room temperature 
conditions. The experiment was stopped when sediment formed and liquid removed from 
the vessel. Total dryness was ensured by movement of solid into glass plate (Finland) and 
drying in the oven (Heraeus Vacutherm, Kendo, Germany)  for 24 hours in temperature 
regimen of 30 °C. Data about evaporation tests are presented in Table 6.
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Table 6. Co-crystallization of theobromine (TB) with theophylline (TP) and caffeine (CAF) 
performed  by  slow  evaporation  method.  TBTP  =  theobromie:theophylline  complex, 
TBCAF = theobromie:caffeine complex.
Complex Mass 
(mg)
Volume of 
water (ml)
Temperature
(°C)
TB TP CAF TB TP CAF
TBTP 160 600 ---- 50 96 96 ----
TBCAF 150 ---- 870 50 94 ---- 97
7.2.2 Co-grinding
In this experiment theobromine was co-crystallized by co-grinding method performed with 
assistive addition of liquid binding agent. Methanol was chosen for this purpose (2902LC, 
Sigma-Aldrikh GmbH,  Germany).  In  preparation  stage homogenous  powder  mixture  of 
each combination was made. There were used such molar ratios as 1 : 1, 1 : 2, 1 : 3 for both 
theobromine:theophylline  and theobromine:caffeine  complexes.  In  case of  theobromine-
theophylline complexes mixtures in 2 : 1 and 1 : 4 molar ratios were also prepared. Data is 
represented  in  table  7.  Each  powder  was  weighed  straight  into  mortar  (Finland)  by 
Sartorius CP3202P (Germany) balance and mixed carefully by pestle (Finland). Addition 
and mixing of powders occurred in three lots by principle of geometric preparation. Lately 
the same procedure was repeated during addition of methanol which was performed by 
pipette  (Finland)  drop-by  drop.   Powders  were  then  sieved  through  0.75  mm  (4 241 
Santasalo-Sohlberg, Finland) sieve and collected into a glass bottle.
Co-grinding was alternatively performed by a ball  mill  (Fritich  Pulverisette,  Germany). 
Powders were weighed into CrNi-grinding bowl of volume 80 ml (Fritich, Germany) with 
use of Sartorius CP3202P (Germany) balance and afterwards 10 balls made of the same 
material with diameter 10 mm were dropped. There were also used tbinding agent. The 
main difference with manual co-grinding was in molar ratio (1 :  5) and this experiment 
was performed only with theobromine:theophylline complex (Table 8). Mixing occurred at 
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speed of 300 rpm during 1 hour. A following milling regimen was repeated 4 times: 15 
minutes milling, 15 minutes reverse milling and 5 minutes for break between each of them. 
When this process was completed powders were dried, sieved and collected.
The same procedure was also performed for prepatation of theophylline complexes (n=3) 
with such carboxylic acids as capric acid (48H2502, Sigma Aldrich, Stenheim, Germany), 
citric acid (Hawkins Inc, Minneapolis, USA), glutaric acid (S41473-347, Sigma Aldrich, 
Stenheim, Germany), maleic acid 99% (32172-100, Sigma Aldrich, Stenheim, Germany), 
malonic acid (027K3737, Sigma-Aldrich Inc, MO, USA), oxalic acid anhyrdate (75688, 
Sigma  Aldrich,  Stenheim,  Germany),  stearic  acid  (Ph.Eur.,  YA99006344,  Yliopiston 
Apteekki,  Helsinki,  Finland),  succinic  acid  (019,  Oriola  OY,  Finland)  and also  HPMC 
(B:MG 09012N21, Methocel E 4000, MW ~ 86 kDa, The Dow Chemical Company, USA). 
Every combination was prepared with addition of methanol. Bowls, equipment, balls and 
mixing regimen were similar to tests performed with theobromine.  Ball mill was rotated in 
this process at higher speed (600 rpm). Data is represented as Table 9 and physicochemical 
properties of co-crystal formers are listed in Table 10.
Table  7.  Co-grinding  of  theophylline  (TP)  with  theobromine  (TB)  and caffeine  (CAF) 
performed manually.
Mass TB
(g)
Mass TP
(g)
Mass CAF
(g)
Molar 
Ratio
Solvent used 
(gtt)
3,6 3,6 ---------- 1 : 1 30
1,8 3,6 ---------- 1 : 2 25
1,2 3,6 ---------- 1 : 3 50
3,6 ---------- 3,88 1 : 1 120
1,8 ---------- 3,88 1 : 2 100
1,2 ---------- 3,88 1 : 3 85
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Table 8. co-grinding of theophylline (TP) with theobromine (TB)  performed machinally.
Mass TB
(g)
Mass TP
(g)
Molar 
Ratio
Solvent used 
(ml)
1,0 5,0 1 : 5 1
Table  9.  Ball  mill  of  theophylline  with  carboxylic  acids  and  polymers.  TPCA  = 
theophylline:capric  acid,  TPCI  =  theophylline:citric  acid,  TPGL = theophylline:glutaric 
acid,  TPML =  theophylline:maleic  acid,  TPMO =  theophylline:malonic  acid,  TPOX = 
theophylline:oxalic acid, TPSU = theophylline-succinic acid, TPST = theophylline:strearic 
acid and TPHP = theophylline:HPMC.
Formulation Mass
TP
(g)
Mass
EXIP
(g)
Mass 
MeOH 
(g)
Molar 
raito
Mass ratio
TPCI 3,00 3,20 0,21 1 : 1 -----
TPCA 3,00 2,87 0,21 1 : 1 -----
TPGL 4,04 2,60 0,21 1 : 1 -----
TPML 2,02 1,30 0,21 1 : 1 -----
TPMO 2,17 0,68 0,22 2 : 1 -----
TPOX 2,06 0,52 0,22 2 : 1 -----
TPSU 4,00 2,62 0,21 1 : 1 -----
TPST 2,00 3,16 0,21 1 : 1 -----
TPHP 4,20 1,40 0,24 ----- 3 : 1
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Table  10.  Physicochemical  properties  of  substances  used  in  co-crystal  formation  with 
theophylline (http://wikipedia.org).
Substance Structure
formula
Molar mass
(g/mol)
Density
(g/cm3)
Melting point
(ºC)
Capric acid C10H20O2 172,26 0,893 31
Citric acid
(anhydrous)
C6H8O7 192,12 1,665 153
Glutaric acid C5H8O4 132,12 1,424 97
Maleic acid C4H4O4 116,10 1,590 135
Malonic acid C3H4O4 104,03 1,619 136
Oxalic acid
(anhydrous)
C2H2O4 90,03 1,900 190
Stearic Acid C18H36O2 284,48 0,847 69,6
Succinic acid C4H6O4 118,09 1,560 186
HPMC
(Methocel E)
C32H60O19 860001 1,390 225-2302
1 a Molar Mass of HPMC is known to be approximately 86 kDa
2 HPMC is known to degrade before melting, at given value range it chars
7.3 Stability tests
7.3.1 Wet granulation
The manual approach to liquid granulation was chosen. It was performed in mortar and 
distilled  water  was  applied  as  binder.  Firstly,  each complex  prepared  by ball  mill  was 
handled by plastic card (Finland) and sieve which had size of 0.75 mm (4 241 Santasalo-
Sohlberg, Finland) to achieve particle size reduction. In next step each complex and pure 
theophylline (n=3) were accurately weighed in mortar (Finland) by Mettler Toledo AX 105 
(Taiwan) balance. Used mass of theophylline was 1 gram and other substances contained 
500 mg or 1 gram of theophylline depending on molecular structure. Afterwards 0.1 or 0.2 
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ml of distilled water was added by 1 ml pipette (EM Hirschmann Germany). An amount of 
aqueous volume was chosen according  to  presence  of  theophylline  in  the test  complex 
(Table 11).  To achieve  mass  ratio of 0.2 g/g (water/theophylline),  water was added on 
Mettler  Toledo AX 105 (Taiwan) balance.  Afterwards both components were mixed by 
pestle  (Finland)  and  powder  card  (Finland)  until  homogenous  powder  was  achieved. 
Granules  were  sieved  through 0.75  mm (4 241 Santasalo-Sohlberg,  Finland)  sieve  and 
collected into a glass bottle. Products of this experiment were stored at room temperature 
(22-25 ºC) for 24 hours and analyzed with Raman spectroscope (5 cm-1 resolution; Control 
development  Inc.,  South Band IN) and also XPRD (D8 Advance,  Bruker AXS GmbH, 
Germany). 
Table  11.  Amounts  of  powders  and  water  used  in  wet  granulation  tests.  TPCA  = 
theophylline:capric  acid,  TPCI  =  theophylline:citric  acid,  TPGL = theophylline:glutaric 
acid,  TPML =  theophylline:maleic  acid,  TPMO =  theophylline:malonic  acid,  TPOX = 
theophylline:oxalic acid, TPSU = theophylline-succinic acid, TPST = theophylline:strearic 
acid, TPHP = theophylline:HPMC and TPH = theophylline.
 
Complex Solid mass
(g)
Water mass
(g)
TPCA 0.98 0.1
TPCI 1.03 0.1
TPGL 0.67 0.1
TPML 0.82 0.1
TPMO 0.79 0.1
TPOX 0.63 0.1
TPST 0.83 0.1
TPSU 1.29 0.1
TPHP 1.34 0.2
TPH 1 0.2
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7.3.2 Water sorption method
Each sample of granules (n=3) was accurately weighed into glass bottle of volume 20 ml by 
Mettler  Toledo  AX  105  (Taiwan)  balance  and  accurately  covered  by  cap.  Afterwards 
vessels were dried in the oven (Heraeus Vacutherm, Kendo, Germany) for 24 at 35 °C. 
Mass change was checked and procedure continued until stable mass was achieved. After 
drying samples were placed into four vacuum desiccators having different relative humidity 
conditions: 0, 54, 75 and 95% and were kept there for 14 days. Each desiccator contained 
different salt solutions: 0% (silica gel), 54% (magnesium nitrate), 75% (sodium chloride), 
95% (disodium hydrogen phosphate). This experiment was performed at room temperature 
conditions (~ 22-24 ºC) for 14 days. All samples were weighed at interval of 3, 4, 12 and 14 
days,  data about mass change was collected and recorded.  For statistics average weight 
changes of each complex in each humidity condition were used.
7.3.3 Methods used in tableting and dissolution
This series of experiments consisted of two parts – final pre-tests and dissolution behaviour 
measurement. The purpose of first was validation of forms for stability and solubility. The 
second one was performed for confirmation.
Each  of  samples  prepared  in  pre  tests  by ball  mill  and  also  pure  theophylline  were 
accurately weighed by Mettler Toledo AX 105 (Taiwan) balance in amounts represented as 
table 12. Mass was chosen so that each crystalline lattice contained approximately 41.5 mg 
of theophylline to achieve solubility value of 8.3 mg/ml. Afterwards, samples were moved 
into glass tubes (Finland) and distilled water in volume of 5 ml was added. Further, neck of 
each tube was coated by polyethylene  and shaken for 1 min by bottle  shaker (Erweka, 
USA). The rotating speed was 3000 rpm. After shaking procedure bottles were allowed to 
stand for 20 min and checked for sediment formation. 
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Table 12. Amounts of powders used in visual solubility. TPCA = theophylline:capric acid, 
TPCI  =  theophylline:citric  acid,  TPGL  =  theophylline:glutaric  acid,  TPML  = 
theophylline:maleic acid, TPMO = theophylline:malonic acid, TPOX = theophylline:oxalic 
acid,  TPST  =  theophylline:strearic  acid,  TPSU  =  theophylline-succinic  acid,  TPHP  = 
theophylline:HPMC and TPH = theophylline.
Formulation
code
Mass 
sample
(mg)
TPCA 81,22
TPCI 85,75
TPGL 71,88
TPML 68,40
TPMO 65,98
TPOX 83,20
TPST 107,12
TPSU 68,65
TPHP 82,76
TPH 41,50
Complexes, which gave suitable result were compressed into tablet (n=6, mass ~ 250 mg) 
by press Korch EK-0 (Berlin,  Germany)  into tensile  strength of 70-80 N. Compressing 
power varied dependently on formulation from 4.2 to 10 kN. Afterwards, units (n=3) were 
tested by intrinsic dissolution method in Sotax AT7 (Basel, Switzerland) paddle apparatus 
for  60  minutes.  This  test  was  performed  in  aqueous  environment  (temperature 
approximately 37 ºC) in volume of 700 ml. Test samples of each vessel were taken with 
Finn  pipettes  (Finland)  of  volumes  200-1000  μl  in  amount  of  1  ml  into  glass  bottles 
(Finland) and equal water volume was added immediately into each vessel. Time intervals 
of sample taking were 5, 10, 15, 25, 35 and 60 minutes after. In final step each probe was 
diluted into 22.5 milliliters of purified water and shaken.
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7.4 Analytical methods
Solid-state changes after each use of each co-crystallization method were checked by two 
devices. The first one was Raman spectrometer  (5 cm-1  resolution; Control development 
Inc., South Band IN) with a fibre optic probe (laser spot size 200 μm, focal length 10 mm; 
InPhotonics,  Norwood  MA)  and  a  diode  laser  (wavelength  785 nm;  Starbright  785  S, 
Torsana Laser Technologies, Denmark) having integration time of 5 s. The second one was 
X-Ray  Powder  Diffraction  (XRPD)  (D8  Advance,  Bruker  AXS  GmbH,  Germany)  in 
symmetrical reflection mode with Cu K radiation at 40 mA and 40 kV. Göbel mirror bent 
multilayer optics were used and the range measured was 5-30˚ (2θ), with steps of 0.05˚ (t=1 
s/step). In some cases Differential Scanning Calorimetry (DSC) (TA Instruments ltd, New 
Castle, England) was applied for confirmation at Nitrogen flow rate 50 ml/min and heating 
rate 10 degrees / min.  Before and after handling samples were weighed into aluminium 
pans by Mettler Toledo AX 105 (Taiwan) and mass change war recorded. Hydration in 
liquid environment was also checked in some cases by optical microscope Zeiss DSM-962 
(Carl Zeiss, Oberkochen, Germany). Concentration of theophylline in dissolution test was 
measured  by LKG Biochrom Ultraspect  (England)  spectrometer  at  wavelength  272 nm 
typical  for theophylline.  All  analytical  procedures  were performed in room temperature 
conditions.
8. RESULTS
8.1. Pre-tests
8.1.1 Aqueous solubility
Theobromine was totally dissolved in such volumes of distilled water as 104 ml (25 ºC), 41 
ml (40 ºC) and 20 ml (60 ºC). Theophylline needed 4 ml (25 ºC), 5 ml (40 ºC) and 3 ml (60 
ºC) of distilled water to be dissolved. For caffeine 5 ml (25 ºC), 2.5 ml (40 ºC) and 1.5 ml 
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(60 ºC) were sufficient. Solubility values calculated by the results of tests are represented in 
Table 13 and Figure 9.
Table 13. Solubility of natural xanthine derivates in aqueous phase.
Sample Concentration
25ºC
(mg/ml)
Concentration
40ºC
(mg/ml)
Concentration
60ºC
(mg/ml)
Theobromine 0.507 0.628 1.29
Theophylline 6.273 15.046 25.153
Caffeine 25.128 40.22 66.97
In case of boiling water, 250 mg of theobromine and complete amounts of theophylline and 
caffeine were used. The needed liquid volumes were 40ml for theobromine and 15 ml (95 
ºC)  for  theophylline  (96  ºC)  and  caffeine  (97  ºC).  Thus  theobromine  achieved  a 
concentration of 6.25 mg/ml, value of theophylline and caffeine was 66,67 mg/ml. 
Current information is in a good agreement with values given in scientific literature and 
also  with  results  of  previous  tests  (Siramorsnak  and  Kennedy  2007)  Statement  about 
aqueous solubility profile based on molecular and crystalline structure was confirmed well 
in this experiment: theobromine was poorly soluble, theophylline was moderate-soluble and 
caffeine was well soluble. Boiling water was able to break tough structure of theobromine 
and dissolve this  substance.  These data  are  in  agreement  with scientific  literature  (The 
Merck Index 2001).
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Figure 9. Solubility profile of xanthines in aqueous environment. 
8.1.2 Organic phase 
According to data represented in handbooks, theobromine is known to be almost insoluble 
or  at  best  slightly  soluble  in  numerous  organic  liquids  (European  Pharmacopoeia  5th 
edition 2007). Results of tests performed in this study confirmed these data. In temperature 
regimen  of  25  ºC  this  xanthine  derivate  showed  low  solubility  in  both  ethanol  and 
methanol. Total insolubility was observed when 1-propanol, isopropanol and acetone were 
applied as solvents. Increase of temperature to 40 ºC did not improve solubility. Heating of 
these  liquids  to  60  ºC  had  little  effect  probably  due  to  rigid  molecular  structure  of 
theobromine. Data are represented in Table 14.
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Table 14. Behaviour of theobromine in organic liquids.
Liquid Concentration
25 ºC
Result Concentration
60 ºC
Result
Ethanol 0.25 Dissolved 0.72 Dissolved
Methanol 0.26 Dissolved 0.61 Dissolved
1-propanol 0.23 Didn't 
dissolve
0.70 Didn't 
dissolve
2-propanol 0.29 Didn't 
dissolve
0.60 Didn't 
dissolve
Acetone 0.23 Didn't 
dissolve
Not performed None
On the contrary, theophylline and caffeine showed superior results in similar series of tests. 
Theophylline  achieved a concentration of 5.02 mg/ml  in ethanol  and in methanol,  1.64 
mg/ml in 1-propanol, 2.45 mg/ml in 2-propanol and 2.23 in acetone. Final concentration of 
caffeine  achieved  such  values  as  10.11  mg/ml  (ethanol),  8.47  mg/ml  (methanol),  4.20 
mg/ml (1-propanol), 1.93 mg/ml (2-propanol) and 8.44 mg/ml (acetone). Results of organic 
phase solubility  tests  correlated  well  with lipophilic  properties of each tested substance 
(Biagi et al 1990). Thus caffeine and theophylline having stronger lipophillic properties 
dissolved better in organic phase than hydrophilic theobromine. 
Theobromine also showed tendency to have superior solubility profile in mineral acids due 
to acidophilic nature (The Merck Index 2001)  Thus hydrochloric acid having concentration 
of 2.03 mg/ml (pH = 2) fully dissolved it. 
8.1.3 Binary solvents
Binary  solvents  assisted  solubility  of  theobromine  as  it  was  expected.  Results  are 
represented  in  table  15  and  figure  10.  Solubility  was  increased  with  the  increase  of 
temperature.  This  tendency was  noticeable  in  all  solvent  systems  used  in  experiments. 
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Solvent that contained water and methanol appeared the poorest solvent for theobromine - 
at temperature of 25 ºC precipitation was noticed, which was a hallmark of poor solubility. 
Failure of this binary phase can be explained with little molecular activity due to limited 
interaction between solid and liquid phase (Williams and Amidon II 1984). Binary solvent 
made of water with ethanol had better molecular activity and water:acetone system could 
be evaluated as an excellent.
Table 15. Solubility profile of theobromine in binary solvents.
Solvent Concentration 
25 ºC
Concentration 
40 ºC
Concentration 
60 ºC
water:ethanol 0.606 1.933 5.115
water:methanol 0.268 0.667 4.084
water:1-propanol 0.712 1.266 5.090
water:2-propanol 0.709 0.893 4.196
water:acetone 0.705 3.054 6.870
Figure 10. Solubility profile of theobromine in binary solvents.
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Theophylline achieved such solubility values as: 15.09 mg/ml (water:ethanol), 15.18 mg/ml 
(water:methanol),  15.09 mg/ml  (water:1-propanol),  12.58 mg/ml  (water:2-propanol)  and 
15.08 mg/ml (water:acetone). Caffeine showed following final concentrations: 16.82 mg/ml 
(water:ethanol),  12.82  mg/ml  (water:methanol),  12.65  mg/ml  (water:1-propanol),  10.22 
mg/ml (water:2-propanol) and 16.70 mg/ml (water:acetone). 
8.1.4. Crystal engineering
Slow evaporation method performed in boiling water produced co-crystals of theobromine 
with both theophylline and caffeine (ATTACHEMENT 1). This conclusion was confirmed 
by XPRD curve with a peak 2θ = 13.30˚ (theobromine:theophylline) and 2θ = 12.20˚; 2θ = 
13.20˚ (theobromine:caffeine). Thus solubility of both compounds was sufficient to allow 
supersaturation state formation and further nucleation (Bladgen et al 2007). Slow rate of 
evaporation  made  possible  to  avoid  spontaneous  nucleation  and  early  precipitation 
(Mersmann and Rennie 2001). However in case of theobromine:theophylline complex there 
was  noticed  undesired  formation  of  co-crystal  hydrous  form,  which  was  confirmed  by 
typical to monohydrous theophylline peaks 2θ = 8.8 and 2θ =11.4 that were present in the 
same XPRD pattern (Airaksinen et al 2003). Hydration of co-crystal is supposed to occur in 
two stages, the first one is hydration of theophylline crystal in aqueous environment (Zhang 
et al 2007). This process is explained by increased water activity and increased interaction 
of theophylline solid form with water – as result  creation of hydrous form takes place, 
which is most stable in humid conditions. In next step crystalline lattice of theobromine 
builds hydrogen bonds with water molecule but not with theophylline (Karki et al 2007). 
Thus the product of this experiment consisted of three components and it did not solve the 
problem of reduced bioavailability due to great energy required for decomposition.
Crystallization  experiment  preformed  by  solid-state  grinding  was  unsuccessful 
(ATTACHEMENT 2).  The  most  probable  reason was inability  of  tested  procedures  to 
connect molecules to each other by hydrogen bonds (Blagen et al 2007). Small volume of 
methanol used in co-grinding tests couldn't assist this essential step. 
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8.2. Crystallization
Products  of  all  experiments  performed  by  ball  mill  technique  appeared  as  white,  dry 
crystalline  powders except  theophylline:capric  acid  and  theophylline:stearic  acid 
combinations. In the case of first one, a white semi-liquid substance was noticed, which 
transformed within  cooling  into white-grey slippery agglomerates.  Result  of  interaction 
between theophylline and stearic acid was similar. 
According  to  data  produced  with  analytical  methods  there  were  constructed  such  co-
crystals  as  theophylline:citric  acid,  theophylline:glutaric  acid,  theophylline:maleic  acid, 
theophylline:malonic  acid,  theophylline:oxalic  acid,  and  also theophylline:succinic  acid. 
This tendency can be explained by high ability of both theophylline and hydroxylic acids 
molecules to build hydrogen bonds (Trask et al 2006).  As it is seen in XPRD patterns 
several  peaks  identify  presence  of  a  co-crystal  (ATTACHEMENT  3):  2θ  =  13.30˚ 
(theophylline:citric  acid),  2θ  =  12.65˚  (theophylline:glutaric  acid),  2θ  =  24.25˚ 
(theophylline:maleic  acid),  2θ  =  8.95˚  (theophylline:malonic  acid),  2θ  =  14.00˚ 
(theophylline:oxalic acid), 2θ = 22.10˚ (theophylline:succinic acid). 
Raman  spectras  of  those  combinations  confirmed  presence  of  new  bonds 
(ATTACHEMENT 4). Thus there were detected numerous shifts: characterizing O=C-N 
bending (562 cm-1 for theophylline:glutaric acid, 584 cm-1 for theophylline:maleic acid, 576 
cm-1 for theophylline:malonic acid and theophylline:oxalic acid);   characterizing H-N=C 
(1243  cm-1 for  theophylline:glutaric  acid,  1235  cm-1 for  theophylline:malonic  acid); 
characterizing  C=O  stretch  (1687  cm-1 for  theophylline:citric  acid,  1707  cm-1 for 
theophylline:maleic acid and theophylline:oxalic acid, 1708 cm-1 for theophylline:malonic 
acid) (Jørgensen et al 2002; Gunasekaran et al 2005). In case of theophylline:succinic acid 
there was noticed shifting at 987 cm-1, which referred to N=C-H deformation (Gunasekaran 
et al 2005). There wasn’t detected any change in graphs of theophylline:capric acid and 
theophylline:stearic acid (ATTACHEMENT 5). 
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According to DSC analysis (ATTACHEMENT 6), theophylline:succinic acid complex had 
melting point of 107.71 ˚C (∆H = 53.07 J/g) while for pure succinic acid it was equal to 
116.49 ˚C (∆H = 137.08 J/g). Melting point of theophylline achieved in this experiment 
was equal to 271.13 ˚C (∆H = 150.11 J/g). It must be noticed, that pure succinic acid and 
theophylline:succinic acid complex were heated only to 150 ˚C while melting point of this 
substance was known to have a value of 186 ˚C. This regimen was chosen to according to 
the value of boiling point (235 ˚C) being lower than melting point of theophylline. Thus 
possible damage of analytical equipment was avoided. 
As a co-crystal  formation mechanism,  one can consider action of two carbonyl  oxygen 
atoms as donors and single basic nitrogen as acceptors (Karki et al 2007). The N-H group 
also plays a donor role. As result there’re potentials for formation of O-H..O and O-H..N 
hydrogen bonds. This structure is supposed to occur between theophylline molecule and 
carboxylic residue. 
Unlike previously listed carboxylic co-crystal formers, capric and stearic acid have only 
one  carboxylic  residue  linked  to  a  long  hydrocarbon  chain  (Figure  11).  They are  less 
available for any kind of construction based on hydrogen bonds and this phenomenon is 
seen  clearly  in  results.  No  new  crystalline  complex  was  formed  according  to  Raman 
(ATTACHEMENT  5)  and  XPRD  graphs  (ATTACHEMENT  7)  in  case  of 
theophylline:stearic  acid  complex.  A  new  peak  was  noticed  in  XPRD  pattern  of 
theophylline:capric  acid  complex  at  2θ=13.45˚  (ATTACHEMENT 7).  Results  of  DSC 
analysis  (ATTACHEMENT 8) were:  melting  point  at  30.67 ˚C (∆H=89.17) while pure 
capric  acid  had  31.62  ˚C  (∆H=150.53).  These  data  indicated  possible  crystal  lattice 
modification  and  presence  of  hidden  co-crystal  in  theophylline:capric  acid  molecular 
complex. These two acids may have an ability to form co-crystals. Molecules of glutaric, 
maleic,  malonic,  oxalic,  succinic  acids  are  known  to  possess  two  carboxyl  functional 
groups and citric acid  has three hydroxylic residues (Figure 11). 
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In the case of  HPMC analytical  techniques  did  not  show formation  of  new crystalline 
lattice (ATTACHEMENT 9).  This polymer exists as a chain consisting of many monomers 
and each of them has hydroxyl  group in  exterior  state  (Katzhendler  et  al  1998).  These 
groups have high ability to form intermolecular hydrogen bonds with exterior OH- and NH-
sites of theophylline but  this type of interaction is not referred to as a co-crystal. Such sort 
of complex can be classified as a two phase system: theophylline nuclei and HPMC core.
Figure 11. Molecular structures of substances used in ball-milling. A = Capric acid, B = 
Citric acid, C = Glutaric acid, D = Maleic acid, E = Malonic acid, F = Oxalic acid, G = 
Stearic acid, H = Succinic acid, I = HPMC monomer unit (http://www.chemblink.com)
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8.3. Stability and solubility
8.3.1 Wet granulation tests
Presence of hydrate was noticed after performing wet granulation in mass proportion of 0.2 
g/g  in  pure  theophylline  and also  in  theophylline:citric  acid,  theophylline:glutaric  acid, 
theophylline:maleic acid and theophylline:oxalic acid systems.  Co-crystals  or alternative 
structures containing in addition to theophylline capric, succinic, malonic, stearic acids and 
HPMC resisted hydration in these conditions and by this reason they were granulated also 
at a mass ratio of 0.4 g/g as in critical conditions. Method of wet granules preparation is 
described in chapter 7.3.1. The only difference was in amount of water, which had value of 
0.2 g. A formation of theophylline monohydrate could be clearly detected by Raman in 
regions having potential  to hydrogen bonding (ATTACHEMENT 10, ATTACHEMENT 
11): 1720–1650 cm-1 (C=O stretch) and 550 cm-1 representing O=C-N bend (Jørgensen et al 
2002). A characteristic shift towards higher intensity in area of 550 cm-2 and relative curve 
changes in area of 1720-1650 cm-2 were detected in curves belonging to complexes, which 
didn’t  prevent  process  of  hydration.  Curves  belonging  to  molecular  combinations  with 
physical  enhancement  ability  were  identical  or  almost  identical  to  curve  of  anhydrous 
theophylline  (ATTACHEMENT  10,  ATTACHEMENT  11).  In  XPRD  patterns  of 
complexes  where hydrate  was formed one could notice  characteristic  peaks  of  hydrous 
theophylline 2θ = 8.8 or 2θ = 11.4 (ATTACHEMENT 12), when complexes passed through 
wet granulation without solid-state change peaks of andyhrous form of theophylline at 2θ = 
7.1 and 2θ = 12.6 were detected (Airkaksinen et al 2003). In patterns of theophylline:capric 
acid  and  granulated  theophylline there  were  peaks  corresponding  to  both  hydrate  and 
anhydrous  forms.  This  fact  suggested  possible  existence  of  mixture  containing  both 
structures. Curve of theophylline:succinc acid (mass ratio 0.4 g/g) provided information, 
which  contradicted  to  Raman  results.  Some patterns  did not  provide information  about 
theophylline  solid  state  conditions.  This  took  place  in  case  of  theophylline:citric  acid, 
theophylline:oxalic  acid and theophylline:stearic  acid (mass ratio 0.4 g/g). These results 
were  supposedly  affected  by  rapid  pass  of  radiation  through  granules  (Jørgensen et  al 
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2002). Thus XPRD appeared a less reliable analytical method than Raman in case of solid 
state determination.
The mechanism of hydration inhibition was probably successful competition between water 
molecules and solid co-crystal components for hydrogen bonding sites in the theophylline 
molecule (Trask et al 2006). Total or partial co-crystal dissociation into theophylline and 
carboxylic acid can take place under critical humidity conditions. Thus there appeared sites 
available for hydrogen interaction between water and xanthine derivate and further hydrate 
formation occurred.
A long hydrocarbon chain in molecules of both capric and stearic acid has a hydrophobic 
behaviour and these carboxylic acids have low water activity (Zhu et al 1996).  In this case 
carboxylic  residues  were  occupied  by  hydrogen  bonds  formed  with  theophylline.  This 
construction explains well good water resistance ability of these molecular combinations. A 
“core” structure of theophylline:HPMC molecular complex leads also to hydrate protection 
- interior hydroxyl- and carboxyl groups of this polymer interact with theophylline, while 
exterior site is able to add water molecules surrounding this structure also by building of 
hydrogen bonds (Katzhendler et al 1998) Movement of hydrous phase towards theophylline 
“nuclei” is avoided and thus competition process leading to hydrate  formation takes no 
place.  Theophylline  is  known  to  convert  into  hydrous  form  existing  in  less  humid 
conditions (below 0.1 g/g) (Airaksinen et al 2003). 
8.3.2 Water sorption
There was no growth of mass during storage in desiccators having air relative humidity of 
0, 54 and 75% RH. On the contrary, in conditions where humidity had a value of 95% mass 
change was noticed. As it was expected, theophylline samples increased weight noticeably. 
In case of other complexes there was no detected water sorption. This result confirmed high 
hydrate formation ability of theophylline. The result of this test showed ability to prevent 
hydrate  formation of tested samples  and also  hydrophobic  nature of theophylline:capric 
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acid and theophylline:stearic acid molecular combinations. Thus critical humid conditions 
for theophylline was found between 75% and 95% RH and they can be classified as high 
(Amado et al 2007).
Figure 12. Water sorption of theophylline anhydrous at 95% RH
8.3.3 Tablet dissolution
By  dissolution  pre-tests,  only  theophylline:HPMC  complex  has  shown  an  appropriate 
solubility profile. In bottles with others sediment was present. Microscope suggested that 
this  complex was able to inhibit  hydrate  formation.  Theophylline:HPMC crystals  had a 
regular  squared  form,  which  differed  strongly  from needle-like  shape  of  monohydrate 
(Figure  12).  For  comparison,  a  sample  was  taken  from  the  tube  containing 
theophylline:succinic acid combination and it also looked like hydrous form (Figure 13). 
This experiment confirmed conclusion on lower potential of this combination for physical 
stability improvement.
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Figure  13.  Microscope  pictures  (x20)  of  theophylline  monohydrate  (A), 
theophylline:HPMC (B) and theophylline:succinic acid 
As it was expected, tablets compressed from theophylline:HPMC powder showed greater 
active ingredient release during intrinsic dissolution tests compared to tablets compressed 
from pure theophylline. Released amount of the former was 22.07% (w/w) compared to 
16.69%  of  the  latter  (Figure  14).  In  the  beginning  of  experiment  tablets  of  pure 
theophylline demonstrated better profile of release. This phenomenon could be explained 
by  prolonged-release  profile  of  the  theophylline:HPMC  matrix.  The  tablet  surface  had 
longer contact time with aqueous media and thus transition of anhydrous form into hydrous 
one took place (Debanath and Suryanarayanan 2004). Further, water penetrated into deeper 
layers  of  tablet  towards  nuclei  and  this  phenomenon  affected  the  dissolution  profile. 
Contrary, HPMC was able to intake water and thus prevent or at least inhibit formation of 
theophylline hydrate (Moji Adeyele et al 1995). Thus HPMC had a superior potential of 
hydrate formation inhibition. 
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Figure 14. Drug release profile of tablets containing theophylline and theophylline:HPMC
9. CONCLUSION
Measurement and impovement of solubility profiles of xanthine and xanthine derivates is 
an extensively reserached topic. Most previous studies included two molecules belonging 
to this group  – theophylline and caffeine. Exploration of third natural derivate theobromine 
is more problematic due to such physicochemical properties as rigid construction and high 
melting  point.  Limited  therapeutic  usage  of  theobromine  compared  to  other  natural 
xanthines has also an effect on the number of studies. This study confirmed poor solubility 
of theobromine in water and various organic liquids as well as practical inability to interact 
with other solids. This is explained with crystalline structure of this substance, which is 
witnessed by the fact of high melting point. Formation of co-crystals with theophylline and 
theobromine in boiling water conditions appears the only way to dissolve current molecule. 
However this  method is  not  recommended for practical  application due to high risk of 
hydrate formation, which was also detected in this study. 
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Theophylline and caffeine demonstrated excellent solubility and there wasn't great need in 
improvement of this parameter. Theophylline has a strong potential of hydration, which is 
known  as  most  common  factor  reducing  bioavailability  of  this  xanthine  derivate  in 
pharmaceutical  practice.  According  to  results  of  previous  research,  transition  of 
theophylline into monohydrous form occurs at low humid conditions (less than 0.1 g/g) and 
pharmaceutical  excipients  provide  at  best  a  small  preventive  effect.  Therefore  crystal 
engineering was chosen as a relatively simple and low cost modern technique. Pilot tests 
suggested a solid co-grinding by ball mill as a most promising approach despite its inability 
to launch theobromine co-crystallization. In comparison with slow evaporation ball milling 
proved to be more simple and applicable for greater amount of substances and required less 
time  to  perform.  Pollution  is  also avoided due to  absence  of  toxic  organic  liquids  and 
molecular  complexes  produced by solid-state grinding are safer.  Final results  were also 
impressive – theophylline built co-crystal with almost all carboxylic acids (citric, glutaric, 
maleic,  malonic,  oxalic,  succinic).  Complexes  of  theophylline:capric  acid  and 
theophylline:stearic acid are supposed to be hidden co-crystals and they requires deeper and 
wider research. Complex containing theophylline and HPMC could not be classified as a 
co-crystal,  but there were interactions maintained by hydrogen bonds. Co-crystallization 
appears a very reilable technique, which can solve the problem of physical stability during 
storage and manufacture procedures, probably by occupation of hydrogen bonding sites by 
alternative  structures  making  thus  interaction  with  water  impossible.  Some  complexes 
prepared during this study had ability to prevent hydration at high (0.2 g/g mass ratio) and 
extremely high (0.4 g/g mass ratio) humid conditions, while excipients failed to prevent this 
process even at noticeably lower water mass ratios. Probably the most important outcome 
of this study is the theophylline:succinic acid cocyrtsal, which was produced for the first 
time. A theophylline-HPMC complex has superior properties – despite excellent hydrate 
formation resistance ability, it improves noticeably solubility. 
Based on these results, one may conclude that crystal engineering shows great potential for 
direct  and  indirect  solubility  enhancement.  The  former  means  methods,  which  lead  to 
improved solubility and the latter – the ways leading to improved physical stability. The 
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solubility  profile  at  least  doesn't  decrease.  Crystalline  structure  may  have  singnificant 
importance because problem of reduced physical stability due to hydrate formation is very 
common  in  pharmacy.  Co-crystallization  provides  protection  against  humid  conditions 
during formulation and production of most dosage forms and also during storage. The latter 
is especially actual for southern countries having wet climate. The greatest benefit gained 
by  co-crystals  may  be  in  reduction  of  pharmaceutically  active  substance  load  in 
formulation, which leads to reduction of side-effects and is beneficial for patients.
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ATTACHEMENT 1
XPRD patterns of co-crystals containing xanthines prepared by slow evaporation method.
Theobromine:Theophylline co-crystal.
Theobromine:Caffeine co-crystal.
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ATTACHEMENT 2
XPRD patterns of complexes containing xanthines prepared by manual co-grinding and ball-
milling.
Theobromie:Theophylline complexes prepared by manual co-grinding.
Theobromie:Caffeine complexes prepared by manual co-grinding.
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Theobromine:Theophylline complex (1:5) prepared by ball-milling.
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ATTACHEMENT 3
XPRD patterns of co-crystals containing Theophylline and carboxylic acids prepared by ball-
milling.
Theophylline:Citric Acid co-crystal.
Theophylline:Glutaric Acid co-crystal.
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Theophylline:Maleic Acid co-crystal.
Theophylline:Malonic Acid co-crystal.
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Theophylline:Succinic Acid co-crystal.
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ATTACHEMENT 4
Raman spectras of co-crystals containing Theophylline and carboxylic acids prepared by ball-
milling.
Theophylline:Citric Acid co-crystal.
Theophylline:Glutaric Acid co-crystal.
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ATTACHEMENT 5
Raman spectras of Theophylline:Capric Acid and Theophylline:Stearic Acid complexes prepared by 
ball-milling.
Theophylline:Capric Acid complex.
Theophylline:Stearic Acid complex.
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ATTACHEMENT 6
DSC thermogram of Theophylline:Succinic Acid co-crystal.
Theophylline:Succinic Acid co-crystal.
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ATTACHEMENT 7. XPRD patterns of Theophylline:Capric Acid and Theophylline:Stearic Acid 
complexes.
Theophylline:Capric Acid complex.
Theophylline:Stearic Acid complex.
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ATTACHEMENT 8
DSC theormogram of Theophylline:Capric Acid complex prepared by ball-milling.
Theophylline:Capric Acid complex.
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ATTACHEMENT 9
XPRD pattern and Raman spectra of Theophylline:HPMC (3:1) complex prepared by ball-milling.
XPRD pattern.
Raman spectra.
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ATTACHEMENT 10
Raman spectras of granules prepared at mass ratio 0.2 g/g.
Theophylline:Capric Acid (550 cm-1).
Theophylline:Capric Acid (1720-1650 cm-1). 
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Theophylline:Stearic Acid (550 cm-1).
Theophylline:Stearic Acid (1720-1650 cm-1).
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ATTACHEMENT 11
Raman spectras of granules prepared at mass ratio 0.4 g/g.
Theophylline:Capric Acid (550 cm-1).
Theophylline:Capric Acid (1720-1650 cm-1).
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ATTACHEMENT 12
XPRD patterns of granules.
Theophylline:Capric Acid (0.2 g/g).
Theophylline:Capric Acid (0.4 g/g).
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